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ABSTRACT	  Class	   I	   phosphoinositide-­‐3	   kinases	   (PI3Ks)	   generate	   PtdIns(3,4,5)P3	   to	   activate	  cell	   signaling	   cascades	   essential	   to	   cell	   growth,	   differentiation	   and	   survival,	   and	  are	  essential	  to	  the	  function	  of	  innate	  and	  adaptive	  immunity.	  The	  generation	  of	  a	  vast	  array	  of	  newly	  developed	  PI3K	  inhibitors	  to	  treat	  cancer	  poses	  the	  question	  of	  their	  use	  in	  the	  modulation	  of	  pathological	  immune	  reactions	  like	  autoimmune	  diseases,	   or	   the	   effect	   of	   these	  drugs	   in	   the	   anti-­‐tumor	   immune	   reactions.	  Here,	  the	   role	   of	   PI3K	   in	   adaptive	   immune	   reactions	   and	   data	   concerning	   the	   use	   of	  inhibitors	  to	  control	  immune	  responses	  are	  reviewed.	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RESUMEN	  
Las	  fosfatidilinositol	  3-­‐cinasas	  de	  clase	  I	  en	  la	  inmunidad:	  Efecto	  de	  inhibidores	  en	  
respuestas	  inmunes	  y	  autoinmunes	  Las	   fosfatidilinositol	   3-­‐cinasas	   (PI3K)	   de	   clase	   I	   dan	   lugar	   a	   fosfolípidos	  trifosforilados	   (PtdIns(3,4,5)P3)	   que	   son	   clave	   en	   las	   señales	   de	   crecimiento,	  diferenciación	   y	   la	   supervivencia	   de	   las	   células	   y	   son	   esenciales	   para	   el	  funcionamiento	  de	   la	   inmunidad	   innata	  y	   adaptativa.	   Los	  nuevos	   inhibidores	  de	  PI3K	   generados	   para	   el	   tratamiento	   de	   tumores	   pueden	   ser	   útiles	   en	  inmunoterapia,	   especialmente	   en	   enfermedades	   autoinmunes,	   y	   ha	   de	  investigarse	   su	   impacto	   en	   la	   inmunidad	   anti	   tumoral.	   Se	   revisa	   el	   papel	   de	   las	  PI3K	   de	   clase	   I	   en	   las	   respuestas	   inmunes	   adaptativas,	   y	   los	   datos	   conocidos	  relativos	  al	  efecto	  de	  inhibidores	  en	  respuestas	  inmunes	  adaptativas.	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1.	  INTRODUCTION	  This	   review	   focuses	   on	   the	   use	   and	   possible	   applications	   of	  phosphoinositide-­‐3	   kinase	   (PI3K)-­‐specific	   inhibitors	   to	   modulate	   immune	  responses,	  with	  an	  emphasis	  on	  T	  lymphocyte-­‐dependent	  adaptive	  responses.	  Phosphoinositide-­‐3	   kinases	   (PI3Ks)	   are	   enzymes	   that	   phosphorylate	   the	  OH-­‐	   group	   at	   the	   D3-­‐position	   of	   the	   inositol	   ring	   of	   inositol-­‐containing	   lipids	  (PtdIns)	   located	   in	   inner	   leaflet	  of	  membrane	  bilayers.	   In	  this	  way,	   they	  generate	  intracellular	  phosphorylated	  inositol	  lipids	  (PtdInsP)	  that	  serve	  to	  anchor	  cytosolic	  enzymes	   facilitating	   interaction	   with	   their	   substrates	   and/or	   their	   activation,	  initiating	   different	   cell	   signaling	   cascades	   (Figure	   1)	   (reviewed	   in	   (1-­‐5)).	   This	   is	  mediated	   by	   membrane	   translocation	   of	   different	   effector	   proteins	   that	   possess	  domains,	   like	   the	   Pleckstrin	   homology	   domain	   (PH),	   the	   Phox	   homology	   domain	  (PX)	  or	  the	  FYVE	  domain,	  specific	  for	  distinct	  phosphorylated	  inositides	  (Figure	  1).	  These	   effector	   proteins	   are	   involved	   in	   the	   regulation	   of	   many	   essential	   cell	  functions	   including	   cell	   survival,	   growth,	   and	   proliferation.	   Not	   surprisingly,	  different	   signals	   essential	   to	   the	   function	   of	   cells	   of	   the	   immune	   system	   activate	  PI3K	  activity.	  For	  instance,	  in	  lymphocytes	  PI3K	  activity	  is	  enhanced	  upon	  antigen	  activation,	   engagement	   of	   costimulatory	   molecules,	   binding	   of	   cytokines	   or	  quimiokines	   to	   their	   receptors,	   or	   integrin-­‐mediated	   adhesion.	   Thus,	   PI3Ks	   are	  prime	  targets	  for	  immunomodulatory	  strategies.	  Differences	   in	   protein	   structure,	   regulation	   of	   activity,	   and	   lipid	   substrate	  preference	  define	  three	  different	  classes	  of	  PI3K,	  namely	  class	  I,	  class	  II	  and	  class	  III	  PI3K	  (Figure	  1,	  2).	  In	  mammals	  there	  are	  eight	  different	  PI3K	  isoforms.	  Of	  them,	  four	  are	  class	   I	  PI3Ks	  (p110α,	  p110β,	  p110γ	  and	  p110δ),	   three	  belong	   to	  class	   II	  PI3K	  (PI3K-­‐C2α,	  PI3K-­‐C2β,	  PI3K-­‐C2γ)	  and	  the	  vacuolar	  sorting	  protein	  34	  (VPS34)	  is	  the	  only	  class	  III	  PI3K.	  Class	  I	  are	  PI3Kinases	  specific	  for	  PtdIns(4,5)P2	  and	  play	  a	  major	   role	   in	   signal	   transduction	   induced	   by	   receptors	   that	   activate	   protein	  tyrosine	  kinases	  (class	  IA	  PI3K)	  or	  by	  receptors	  coupled	  to	  small	  GTPases	  (class	  IB	  PI3K).	   Class	   II	   and	   III	   PI3Kinases	   phosphorylate	   PtdIns.	   Class	   II	   have	   a	   role	   in	  signal	  transduction,	  but	  many	  aspects	  of	  their	  biology	  are	  not	  well	  known;	  Class	  III	  have	  a	  role	  in	  vesicle	  trafficking.	  	  	  	  
Class	  I	  phosphoinositide	  3-­‐kinases	  in	  immunity…	  	  
	  93	  	  
	  
Figure	   1.-­‐	  A	   summary	   of	   phosphoinositide	   phosphorylation/dephosphorylation	   steps	   in	   the	   cell	  membrane	   is	   shown.	   These	   phosphoinositides	   recruit	   proteins	   endowed	   with	   phosphorylated	  inositol	   lipid-­‐binding	   protein	   domains	   that	   serve	   to	   cell	   signaling.	   Phosphorylation	   and	  dephosphorylation	   steps	   are	   indicated	   by	   red	   and	   blue	   arrows,	   respectively;	   steps	   where	   PI3K	  kinases	   intervene	   are	   shadowed	   in	   red;	   Inositol	   phosphate	   phosphatases	   are	   shadowed	   in	   blue;	  effector	   protein	   domains	   binding	   to	   different	   phosphorylated	   inositol	   lipids	   are	   in	   yellow.	  Abbreviations:	   FAB1:	   PtdIns(3)P	   5-­‐kinase;	   FYVE:	   Fab	   1	   YOTB	   Vac	   1	   and	   EEA1	   domain;	   INPP4:	  Inositol	   polyphosphate	   4-­‐phosphatase;	   INPP5:	   Inositol	   polyphosphate	   5-­‐phosphatase;	   MTM:	  Myotubularin;	   PH:	   Plecstrin	   homology	   domain;	   PI3K:	   Phosphoinositide-­‐3	   kinase;	   PLC:	  Phospholipase	   C;	   PROPPIN:	   β-­‐propeller	   that	   bind	   phosphoinositide	   species	   domain;	   PtdInsP:	  Phosphorylated	   inositol	   lipids;	   PTEN:	   Phosphatase	   and	   Tensin	   Homologue;	   PX:	   Phox	   homology	  domain;	  SHIP:	  SH2	  domain-­‐containing	  inositol	  5’-­‐phosphatase.	  
2.	  CLASS	  I,	  II,	  III	  PI3K,	  AND	  PI3K-­‐LIKE	  KINASES	  Of	  interest	  to	  the	  development	  and	  effect	  of	  PI3K-­‐specific	  inhibitors,	  PI3Ks	  have	   sequence	   similarity	   with	   a	   number	   of	   other	   related	   serine	   and	   threonine	  protein	  kinases	  collectively	  known	  as	  “PI3K-­‐like	  protein	  kinases”,	  or	  PIKK.	  These	  PIKK	  play	  a	  role	  in	  the	  cellular	  response	  to	  stresses	  like	  DNA	  damage	  or	  replication	  block,	  mRNA	   splicing	   errors	   and	  nutrient	   deprivation.	   Importantly,	   PIKK	   include	  one	   of	   the	  main	   downstream	   effectors	   of	   class	   I	   PI3K	   activation	   in	   lymphocytes,	  namely	  the	  mechanistic	  target	  of	  the	  immunosuppressant	  Rapamycin	  (mTOR),	  but	  also	  the	  ataxia-­‐telangiectasia	  mutated	  protein	  (ATM),	  the	  ataxia-­‐	  and	  Rad3-­‐related	  protein	   (ATR),	   and	   the	   DNA-­‐dependent	   protein	   kinase	   catalytic	   subunit	   (DNA-­‐PKcs)	   (6,7).	   DNA-­‐PK	   is	   required	   for	   the	   activation	   of	   the	   non-­‐homologous	   end-­‐joining	  pathway	  to	  repair	  double-­‐strand	  DNA	  breaks	  induced	  by	  ionizing	  radiation.	  Furthermore,	   DNA-­‐PK	   activates	   protein	   kinase	   B	   (Akt),	   another	   primer	   target	   of	  class	  I	  PI3K,	  and	  is	  particularly	  important	  to	  lymphocyte	  biology	  as	  its	  mutation	  is	  a	   cause	   for	   severe	   combined	   immunodeficiency	   (8).	   Structural	   homology	   among	  PI3K	  isoforms,	  or	  between	  PI3K	  and	  PIKK	  (6)	  has	  the	  consequence	  that	  frequently,	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PI3Kinase	  inhibitors	  are	  specific	  for	  more	  than	  one	  isoform,	  or	  that	  PI3K	  inhibitors	  primarily	   aimed	   at	   inhibiting	   class	   I	   PI3Kinases	   significantly	   inhibit	   PIKK	   like	  mTOR	  or	  DNA-­‐PK	  (9).	  	  
3.	   CLASS	   IA	   AND	   CLASS	   IB	   PI3KINASES:	   STRUCTURE	   AND	   ACTIVATION,	  
CONTROL	  BY	  PHOSPHATASES	  Class	  I	  PI3Kinases	  are	  heterodimers	  formed	  by	  one	  catalytic	  of	  110	  kDa	  and	  one	  regulatory	  subunit	  of	  variable	  size	  (Figure	  2).	  According	   to	   the	  nature	  of	   the	  regulatory	  subunit	  they	  bind	  to,	  and	  the	  mode	  they	  are	  classically	  activated,	  class	  I	  PI3Kinases	  are	  further	  divided	  into	  class	  IA	  (Figure	  2A	  and	  B)	  and	  class	  IB	  (Figure	  2C).	  The	  former	  (catalytic	  subunits	  p110α,	  p110β,	  and	  p110δ)	  bind	  to	  any	  of	  five	  regulatory	   subunit	   isoforms	   (p85α,	   p55α,	   p50α,	   p85β,	   and	   p55γ)	   all	   possessing	  two	   SH2	   domains	   separated	   by	   an	   alpha-­‐helix	   inter-­‐SH2	   domain	   (iSH2)	   that	  interacts	  with	  catalytic	   subunits;	  Class	   IA	  catalytic	   subunits	  are	  characteristically	  activated	  through	  tyrosine	  kinase-­‐dependent	  mechanisms.	  Phosphorylation	  of	  the	  Tyr	  residues	  of	  Tyr-­‐x-­‐x-­‐Met	  is	  the	  initial	  step	  inducing	  binding	  of	  SH2	  domains	  that	  are	  conserved	  in	  all	  class	  IA	  regulatory	  isoforms.	  The	  p85,	  but	  not	  the	  p50	  or	  p55	  regulatory	   isoforms	  have	  additional	  SH3,	  proline	  rich	  and	  BCR-­‐homology	  GTPase	  activation	  domain	  (BH-­‐domain)	  that	  might	  mediate	  binding	  to	  small	  G	  proteins	  of	  
the	  Rho/Rac/cdc42	  family.	  On	   the	   other	   hand,	   class	   IB	   catalytic	   subunit	   p110γ	   binds	   to	   regulatory	  subunits	   p101	   and	   p87	   (Figure	   2C).	   Subunit	   p101	   is	   the	   main	   subunit	   in	   most	  tissues;	   p101	   and	   p85	   differentially	   help	   in	   G	   protein–coupled	   receptor	   (GPCR)-­‐induced	   PI3K	   activation,	   such	   that	   interaction	   of	   p101	   with	   the	   Gβγ	   chains	   is	  strong	  and	  efficient	  in	  recruitment	  of	  p110γ	  to	  membranes	  whereas	  p87	  interacts	  weakly	  with	   Gβγ	   chains	   and	   recruitment	   of	   p110γ	   needs	   additional	   interactions	  with	  Ras-­‐GTP	  (10).	  	  Class	   I	   catalytic	   subunits	   are	   structured	   in	   domains	  with	   distinct	   function	  (Figure	   2A-­‐C);	   these	   include	   a	   N-­‐terminal	   adaptor	   binding	   domain	   (ABD)	   that	  constitutively	  bind	  regulatory	  subunits,	  a	  Ras-­‐binding	  domain,	   the	  C2	  and	  helical	  domains	  that	  regulate	  the	  association	  with	  regulatory	  subunits,	  and	  one	  C-­‐terminal	  kinase	   domain.	   Interactions	   of	   class	   IA	   p110α	   and	   the	   iSH2	   and	   amino-­‐terminal	  domain	  of	  regulatory	  p85α	  subunits	  have	  been	  determined	  in	  detail	  (11,12).	  In	  the	  steady	   state,	   the	   p110-­‐p85	   heterodimers	   have	   low	   enzymatic	   activity;	   however,	  binding	   of	   SH2	   domains	   to	   phosphorylated	   peptides	   disrupt	   the	   inhibitory	  interactions	   including	   the	   one	   between	   the	   p85	   nSH2	   domain	   and	   the	   helical	  domain	  of	  p110α	  (12,13).	  Given	  the	  inhibitory	  nature	  of	  the	  regulatory	  subunits,	  it	  should	   be	   noted	   that	   there	   are	   clear	   differences	   among	   catalytic	   isoforms	  concerning	  their	  interaction	  strength	  with	  regulatory	  subunits	  (14).	  In	  addition,	  at	  
Class	  I	  phosphoinositide	  3-­‐kinases	  in	  immunity…	  	  
	  95	  	  
least	  in	  certain	  cases	  Ras-­‐family	  proteins	  might	  play	  an	  active	  role	  in	  recruiting	  to	  membranes	  catalytic	  class	  IA	  (15)	  and	  class	  IB	  subunits	  (10).	  
	  
Figure	   2.	   Structure	   of	   the	   catalytic	   and	   regulatory	   subunits	   of	   mammalian	   PI3K	   classes	   and	  subclasses.	  Size	  in	  kDa	  is	  indicated	  in	  the	  name	  of	  class	  I	  PI3K,	  all	  proteins	  are	  represented	  at	  the	  same	   approximate	   scale.	   PI3K	   catalytic	   subunits	   contain	   a	   common	   core	   of	   one	   C2	   domain,	   one	  helical	  domain,	  and	  one	  catalytic	  kinase	  domain.	  Class	  IA	  and	  IB	  catalytic	  subunits	  (α,	  β,	  δ,	  and	  γ)	  are	  the	  product	  of	  single	  genes	  ;	  they	  have	  two	  domains	  N-­‐terminal	  to	  the	  core,	  namely	  an	  adaptor	  binding	  domain	  (ABD)	  that	  binds	  to	  regulatory	  subunit,	  and	  one	  Ras-­‐binding	  domain	  where	  binding	  of	   Ras	   family	   proteins	   activate	   the	   kinase	   activity.	  A;	  B)	   Class	   IA	   catalytic	   subunits	   (α,	  β,	   and	  δ)	  associate	   with	   any	   class	   IA	   regulatory	   subunits	   encoded	   by	   three	   different	   genes.	   Pik3r1	   can	  produce	  three	  different	  proteins	  (p85α,	  p55α	  and	  p50α)	  sharing	  one	  Pro-­‐rich	  region,	  plus	  one	  N-­‐terminal	  and	  one	  C-­‐terminal	  SH2	  domains	  separated	  by	  and	  inter-­‐SH2	  domain	  (iSH2)	  that	  binds	  the	  ABD	  domain	   in	   the	  catalytic	  α,	  β,	   and	  δ	   subunits.	  The	  p85α	   subunit	  has	  one	  N-­‐terminal	  SH3,	  one	  Proline-­‐rich,	   and	  one	  BH	   (BCR	  homology)	  domain;	   the	  p85β	   subunit	   coded	  by	   the	  Pik3r2	   gene	   is	  similar	  to	  p85α	  subunit	  but	  has	  an	  additional	  c-­‐terminal	  Pro-­‐rich	  region.	  The	  p55γ	  subunit	  encoded	  by	  Pik3r3	  and	  p55α	  have	  similar	  structures.	  C)	  Class	  IB	  catalytic	  subunits	  (p110γ)	  bind	  to	  p87	  or	  p101	   class	   IB	   regulatory	   subunits	   endowed	   with	   domains	   able	   of	   associating	   to	   the	   Gα	   and	   Gβ	  subunits	   of	   heterotrimeric	   Guanine	   nucleotide-­‐binding	   proteins	   (G	   proteins)	   that	   initiate	   signals	  delivered	  by	  G-­‐protein	  coupled	  receptors	  (GPCR).	  D)	  Class	  II	  PI3Ks	  do	  not	  have	  regulatory	  subunits,	  and	  seem	  to	  be	  constitutively	  bound	  to	  intracellular	  membranes.	  They	  have	  a	  role	  in	  different	  cell	  functions	  including	  cell	  migration,	  exocytosis,	  and	  apoptosis,	  but	  the	  precise	  mechanisms	  involved	  are	   not	   clear.	   The	   Class	   III	   catalytic	   subunit	   Vps34	   (Vacuolar	   protein	   sorting	   34,	   also	   termed	  PIK3C3)	   is	  part	  of	  a	  heterodimer	  with	   the	  myristoylated	  protein	  Vps15,	   that	   is	   located	   in	   the	  cell	  membranes	   and	   form	   larger	  multi-­‐protein	   complexes	   depending	   on	   the	   particular	   vesicle	   traffic	  process	   considered	   (autophagy,	   phagocytosis,	   endosome	   traffic).	   Vps15	   has	   a	   kinase	   domain	  probably	   inactive,	   HEAT	   domains	   containing	   anti-­‐parallel	   α-­‐helices	   involved	   in	   protein-­‐protein	  interactions;	  and	  WD	  repeats	  that	  serve	  as	  scaffolds	  for	  interaction	  with	  other	  proteins.	  Regulatory	   subunits	   inhibit	   the	   catalytic	   activity	   of	   the	   p110	   subunits	   but	  also	  prevent	  their	  degradation.	  Activation	  of	  PI3K	  begins	  upon	  recruitment	  of	  the	  enzyme	   complex	   through	   regulatory	   subunits	   to	   the	   inner	   side	   of	   membrane	  bilayers	   where	   their	   substrate	   is	   located,	   and	   where	   interaction	   with	   the	  negatively	  charged	  surface	  through	  positively	  charged	  aminoacid	  residues	  further	  stabilizes	   its	   location.	   This	   is	   followed	   by	   interaction	   with	   and	   activation	   of	   the	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catalytic	  subunits	  by	  small	  GTPases	  of	  the	  Ras	  family,	  with	  a	  clear	  selectivity	  of	  the	  different	  catalytic	  subunits	  for	  activation	  by	  distinct	  Ras	  family	  members	  (16).	  The	   signaling	   outcome	   of	   PI3K	   is	   also	   controlled	   by	   the	   activity	   of	  PtdIns(3,4,5)P3	   phosphatases	   that	   are	   essential	   to	   correct	   lymphocyte	   function	  (17-­‐19)	  (Figure	  1,	  3).	  The	  PtdIns(3,4,5)P3	  3-­‐phosphatase	  Phosphatase	  and	  Tensin	  Homologue	   (PTEN)	   controls	   PtdIns(3,4,5)P3	   levels	   by	   generating	   PtdIns(4,5)P2;	  PTEN	   is	   particularly	   important	   to	   control	   basal	   levels	   of	   PtdIns(3,4,5)P3.	   The	  PtdIns(3,4,5)P3	  5-­‐phosphatases	  SHP-­‐1	  and	  SHP-­‐2	  (SH2	  domain-­‐containing	  Inositol	  Phosphatase-­‐1	   and	   -­‐2)	   dephosphorylate	   PtdIns(3,4,5)P3	   levels	   yielding	  PtdIns(3,4)P2.	   Interestingly,	   SHP-­‐1,	   2	   bind	   to	   surface	   molecules	   of	   lymphocytes	  that	  are	  essential	  to	  negatively	  control	  immune	  responses	  including	  CTLA-­‐4,	  PD-­‐1,	  and	  BTLA	  (17).	  
	  
Figure	  3.	  A	  diagram	  of	  class	  I	  PI3K-­‐mediated	  signaling	  in	  T	  (CD4+)	  lymphocytes.	  Class	  IA	  PI3K	  are	  recruited	   to	   the	   cell	   membrane	   and	   activated	   upon	   binding	   of	   ligands	   for	   cytokine	   and	   antigen	  receptors	   or	   CD28	   family	   costimulator	   molecules	   like	   CD28	   or	   ICOS.	   Class	   IB	   subunits	   are	  characteristically	   recruited	   and	   activated	  upon	  binding	  of	   chemokines	   to	   their	  G	  protein-­‐coupled	  receptors.	   Enhanced	   levels	   of	   PtdIns(3,4,5)P3	   (PIP3)	   favor	   the	   recruitment	   and	   activation	   of	  proteins	   containing	   PH	   domains	   including	   Ser	   and	   Thr	   kinases	   like	   PDK1	   and	   Akt,	   Tec	   family	  protein	   Tyr	   kinases	   (Itk),	   phospholipases	   like	   PLC-­‐γ,	   or	   GEF	   like	   Vav.	   Akt	   is	   activated	   by	  phosphorylation	   of	   Thr308	   and	   Ser473	   by	   PIP3–dependent	   activated	   PDK1	   and	   mTORC2,	  respectively.	   Akt	   has	   an	   array	   of	   different	   targets	   involved	   in	   many	   cell	   functions.	   One	   major	  effector	   of	  Akt	   is	   the	  mTORC1	   complex	   containing	   the	   Ser/Thr	   kinase	  mTOR	   and	  Raptor.	   This	   is	  achieved	  by	   inactivation/phosphorylation	  of	   the	  tuberous	  sclerosis	  1	  and	  2	  complex	  (TSC1-­‐TSC2)	  that	  blocks	  RHEB	  (Ras	  homologue	  enriched	  in	  brain),	  a	  small	  GTPase	  and	  mTOR	  activator.	  Through	  phosphorylation	   of	   other	   substrates	   like	   ATG13	   (autophagy-­‐related	   protein	   13),	   S6K,	   4E-­‐BP1,	   or	  HIF-­‐1α,	   mTORC1	   controls	   important	   cell	   processes	   including	   autophagy	   or	   cell	   metabolism.	   Akt	  also	   regulate	   apoptosis	   through	  Bcl-­‐2-­‐associated	  death	  promoter	   (BAD)	  protein	  phosphorylation,	  the	   transcription	   of	   genes	   controled	   by	   FOXO	   transcription	   factors,	   or	   Glycogen	   synthase	   kinase	  (GSK)	  3-­‐mediated	  effects	  on	  cell	  cycle	  and	  metabolism.	  mTORC2	  and	  PDK1	  also	  phosphorylate	  the	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PKCθ	   activated	   by	   diacylglicerol	   (DAG),	   or	   Serum-­‐	   and	   glucocorticoid-­‐inducible	   kinase	   (SGK)	   1.	  PLC-­‐γ	   is	  recruited	  to	  PI3P3	  containing	  membranes	  to	  generate	  IP3	  and	  DAG;	  IP3	   induces	  enhanced	  cytoplasmic	  Ca2+	  levels	  and	  activation	  of	  NF-­‐AT	  transcription	  factors.	  DAG	  activates	  not	  only	  NF-­‐κB	  through	   PKCθ,	   but	   RasGRP	   that	   activates	   the	   Ras	   proteins,	   thus	   enhancing	   PI3K	   and	   other	   Ras-­‐dependent	  signals	  including	  the	  MAPK	  pathway.	  One,	  then,	  faces	  a	  situation	  where	  class	  I	  PI3K,	  an	  enzyme	  essential	  to	  many	  cell	  functions	  is	  regulated	  at	  many	  levels,	  particularly:	  i)	  by	  the	  expression	  levels	  of	  each	   regulatory	   and	   catalytic	   isoform	   of	   PI3K,	   of	   the	   different	   PtdIns(3,4,5)P3	  phosphatases,	  and	  the	  different	  activator	  and	  effector	  proteins	  of	  PI3K;	  and	  ii)	  by	  the	  nature	  of	  the	  signals	  that	  activate	  PI3K	  activity	  in	  different	  cells	  and	  conditions.	  The	  final	  outcome	  of	   the	  cell	  response	  will	  depend	  on	  the	   integration	  of	  all	   these	  factors.	   Furthermore,	   differences	   among	   different	   cells	   and	   tissues	   concerning	  these	  factors	  allow	  for	  distinct	  pharmacological	  effects	  of	  PI3Kinase	  inhibitors	  and	  a	  selective	  intervention	  in	  different	  pathological	  situations.	  As	   a	   general	   rule,	   the	   expression	   of	   class	   IA	   p110α	   and	   p110β	   is	   broad,	  whereas	   class	   IA	   p110δ	   and	   class	   IB	   p110γ	   are	   mainly	   expressed	   by	   cells	   of	  hematopoietic	  origin.	  Among	  class	  I	  PI3K,	  lymphocytes	  express	  readily	  detectable	  amounts	   of	   class	   IA	   p110δ	   and	   class	   IB	   p110γ	   catalytic	   subunits	   that	   are	  characteristic	   of	   leukocytes.	   Interestingly,	   in	   T	   lymphocytes	   class	   IA	   p110α	   is	  expressed	   at	   levels	   similar	   to	   p110δ,	   but	   expression	   of	   p110β	   is	   low	   (14).	   The	  particular	   function	   for	   the	   different	   class	   IA	   regulatory	   subunit	   isoforms	   is	   not	  clearly	   established.	   Among	   class	   IA	   regulatory	   subunits,	   T	   lymphocytes	   express	  low	  amounts	  of	  p85β	  and	  p55γ	  chains	  ((14),	  and	  unpublished	  data),	  so	  p85α	  and	  its	  splicing	  variants	  p55α	  and	  p50α	  are	  the	  main	  regulatory	  subunits	  (14).	  There	  are	  clear	  variations	  in	  the	  abundance	  of	  these	  isoforms	  in	  resting	  and	  activated	  T	  cells.	  Thus,	  resting	  CD4+	  T	  lymphocytes	  have	  similar	  levels	  of	  p85α	  and	  p50α,	  but	  the	  levels	  of	  p50α	  is	  strongly	  reduced	  upon	  activation;	  low	  levels	  of	  p50α	  are	  also	  common	   in	   T	   cell	   lines	   (14).	   In	   turn,	   p50α	   subunits	   bind	   better	   than	   p85α	   to	  phosphorylated	   Tyr-­‐x-­‐x-­‐Met	   motifs	   (14)	   and	   are	   preferentially	   recruited	   to	  immunological	  synapses	  together	  with	  ICOS	  (20).	  However,	  the	  functional	  meaning	  of	  these	  differences	  is	  far	  from	  clear.	  	  
4.	  CLASS	  IA	  AND	  CLASS	  IB	  PI3KINASES:	  MAIN	  MOLECULAR	  MEDIATORS	  In	  lymphocytes	  class	  I	  PI3Kinases	  are	  activated	  through	  different	  receptors	  ((21,22),	   Figure	   3).	   The	   activity	   of	   Src	   and	   Syk	   tyrosine	   kinases	   is	   triggered	   by	  ligand	  binding	  to	  antigen	  receptor	  complexes	  (BCR	  in	  B	  lymphocytes,	  TCR/CD3	  in	  T	   lymphocytes).	  This	  activation	   leads	  to	  phosphorylation	  of	  adaptor	  proteins	   like	  LAT	   and	   TRIM	   in	   T	   cells	   or	   BCAP	   in	   B	   cells.	   Class	   IA	   PI3Kinases	   are	   typically	  recruited	  to	  membranes	  and	  activated	  upon	  phosphorylation	  of	  Y-­‐x-­‐x-­‐M	  motifs	  in	  these	  proteins	  (i.e.	  in	  TRIM)	  or	  by	  means	  of	  adaptor	  proteins	  like	  Grb-­‐2	  or	  Cbl.	  Co-­‐
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stimulatory	   molecules	   like	   CD28	   and	   ICOS	   in	   T	   cells	   and	   CD19	   in	   B	   cells	   also	  possess	  Y-­‐x-­‐x-­‐M	  motifs	  that	  can	  be	  phosphorylated	  to	  directly	  recruit	  PI3Kinases.	  Cytokine	  receptors	  indirectly	  induce	  recruitment	  and	  activation	  of	  class	  IA	  PI3K	  by	  means	  of	  different	  adaptor	  proteins.	  For	  instance,	   in	  IL-­‐2	  signaling	  IL-­‐2	  receptors	  (IL-­‐2R)	   recruits	   class	   IA	  PI3K	  upon	  phosphorylation	  of	  Tyr338	  of	   the	  β	   chain	   that	  allows	  binding	  of	  the	  protein	  adaptors	  SHP2	  and	  Gab2,	  as	  well	  as	  the	  Shc	  and	  Grb	  adaptors	   that	   facilitate	   the	   formation	   of	   Grb-­‐Gab2	   o	   Grb-­‐2-­‐SHPS.	   On	   the	   other	  hand,	   the	   PI3Kinase	   class	   IB	   p110γ	   catalytic	   subunits	   are	   activated	   by	   the βγ	  subunits	  of	  G-­‐coupled	  protein	  chemokine	  receptors	  having	  seven	  trans-­‐membrane	  peptide	   sequences.	   However,	   this	   separation	   among	   PI3K	   subclasses	   is	   not	  absolute,	  as	  on	  one	  hand	  class	  IA	  p110β	  signaling	  through	  G-­‐coupled	  receptors	  has	  been	  observed	  ((23),	  reviewed	  in	  (5)),	  and	  in	  T	  lymphocytes	  tyrosine	  kinases	  like	  Lck	   and	   ZAP-­‐70	   can	   associate	   p110γ	   class	   IB	   subunits	   upon	   antigen	   receptor	  activation	  (24).	  This	  is	  further	  complicated	  in	  lymphocytes,	  where	  p110γ	  mediate	  PI3K-­‐dependent	  chemokine	  signals	  in	  T	  lymphocytes,	  but	  p110δ	  perform	  the	  same	  functions	   in	  B	   lymphocytes	  by	  mechanisms	  not	  well	  understood	  (25,26),	  but	  that	  might	  involve	  tyrosine	  kinases	  or	  Ras	  members	  activated	  by	  quimiokines	  (5).	  Upon	   PI3K	   activation	   PtdIns(3,4,5)P3	   is	   generated	   that	   can	   be	  dephosphorylated	  by	  the	  action	  of	  SHIP	  phosphatases	  to	  yield	  PtdIns(3,4)P2.	  Both	  PtdIns(3,4,5)P3	  and	  PtdIns(3,4)P2	   recruit	  proteins	  with	  plectstrin	  homology	   (PH)	  domains	  to	  cell	  membranes,	  usually	  the	  plasma	  membrane.	  Recruited	  proteins	  can	  then	   be	   activated	   to	   initiate	   signaling	   cascades.	   These	   proteins	   can	   vary,	   as	   PH	  domains	  have	  certain	  selectivity	  concerning	   their	   interaction	  strength	  with	   these	  phosphoinositides.	   In	   lymphocytes	   they	   include	  serine	   threonine	  kinases	   like	   the	  phosphoinositide-­‐dependent	   kinase	   1	   (PDK1)	   or	   Akt	   (PKB),	   Tec	   family	   tyrosine	  kinases	  like	  Itk	  (in	  T	  lymphocytes)	  or	  Btk	  (in	  B	  lymphocytes),	  adaptor	  proteins	  like	  GAB2,	  and	  small	  GTPase	  positive	  (Guanine	  nucleotide	  exchange	  factors	  (GEF)	  like	  Vav)	  or	  negative	  (GTPase	  activating	  factors	  (GAP))	  regulatory	  proteins.	  
4.a.	  Targets	  of	  PI3K:	  PDK1,	  Akt	  and	  mTOR.	  	  In	  many	  cell	  types	  and	  in	  lymphocytes	  too,	  the	  serine	  threonine	  kinase	  Akt	  plays	   a	   key	   mediator	   role	   in	   PI3K	   activated	   signals	   (3,18,27-­‐29).	   Membrane-­‐recruited	  Akt	  is	  activated	  upon	  phosphorylation	  in	  residue	  Thr308	  by	  PDK1	  that	  is	  also	   recruited	   through	  PH	  domains	   and	   activated	  by	   tyrosine	   kinases	   of	   the	   src-­‐family	   kinases	   like	   Lck	   (30).	   Akt	   P-­‐Thr308	   then	   phosphorylates	   substrates	   like	  Caspase	  9,	  BAD	  or	   IKKα	   to	  prevent	  apoptosis,	  GSK3β	   to	   favour	  proliferation,	  and	  the	  mTORC1	  complex	   (the	  Rapamycin	  sensitive	   complex	  of	  mechanistic	   target	  of	  Rapamycin	  (mTOR)	  containing	  Raptor)	  or	  its	  negative	  regulator	  TSC1/2	  to	  favour	  protein	   synthesis	   and	   cell	   growth.	   Akt	   is	   fully	   activated	   by	   phosphorylation	   of	  Ser423	   by	   kinases	   generically	   termed	   PDK2.	   The	   main	   PDK2	   is	   mTORC2,	   the	  Rapamycin-­‐insensitive	  complex	  of	  mTOR	  containing	  Rictor.	  mTORC2	  activation	  is	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also	   PI3K	   dependent	   and	   involves	   its	   association	   with	   ribosomes,	   yet	   the	   exact	  mechanisms	  are	  not	  known	  (29).	  At	   least	  another	  well	  established	  PDK2	  activity	  for	   Ser423	   Akt	   phosphorylation	   is	   mediated	   by	   the	   DNA-­‐PK	   (7,31,32).	   Doubly	  phosphorylated	   Akt	   P-­‐Thr308Ser423	   efficiently	   phosphorylates	   forkhead	  transcription	  factor/forkhead	  box	  (FOXO)	  transcription	  factors	  FOXO1/2	  to	  inhibit	  their	  function,	  with	  important	  consequences	  in	  lymphocytes	  (27,33).	  
4.b.	  Targets	  of	  PI3K:	  GEFs	  and	  Tec.	  	  The	  control	  by	  PI3Ks	  of	   the	  actin	  cytoskeleton	  dynamics	  mediated	  by	  GEF	  stimulation	  of	  the	  Rac	  and	  Rho	  GTPases	  is	  well	  established	  (21).One	  typical	  GEF	  is	  Vav,	  that	  is	  activated	  by	  Src	  and	  Syk	  family	  tyrosine	  kinases	  but	  also	  depends	  on	  its	  PH	  and	  Dbl-­‐homology	  domains	  for	  activity	  (34).	  With	   one	   exception,	   Tec	   family	   tyrosine	   kinases	   including	   BTK	   and	   Itk	  expressed	  in	  B	  and	  T	  lymphocytes	  possess	  an	  N	  terminus	  PH	  domain	  followed	  by	  TH,	   SH3,	   SH2,	   and	   kinase	   domains	   (35,36).	   The	   PH	   domain	   is	   determinant	   to	  recruitment	  of	   these	  Tec	  kinases	   to	  membranes,	  where	   they	   can	   further	   interact	  with	   specific	   Tyr-­‐phosphorylated	   substrates	   and	   activated	   by	   Src	   family	   and	  autophosphorylation.	  Tec	   family	   tyrosine	  kinases	  have	  phospholipase	  C	  enzymes	  like	   PLCγ	   as	   important	   substrates	  within	   signalosomes	   generated	   upon	   receptor	  activation.	  PLCγ	  then	  splits	  PtdIns(4,5)P2	  into	  Diacylglicerol	  and	  Ins(1,4,5)P3	  that	  in	   turn	   are	   necessary	   to	   activate	   the	   Ser/Thr	   kinases	   PKCθ	   and	   hence	   the	  Ras/MAPK	   and	   the	   IKK/NFκB	   pathways,	   or	   the	   Ins(1,4,5)P3-­‐Ca2+-­‐dependent	  activation	  of	  NFAT	  family	  of	  transcription	  factors	  (Figure	  3).	  
4.c.	  Targets	  of	  PI3K:	  PDK1-­‐dependent,	  Akt-­‐independent.	  	  PDK1	   can	   associate	   to	   and	   activate	   additional	   substrates	   that	   are	   not	  dependent	   on	   Akt	   including	   the	   Ser/Thr	   kinases	   PKCθ	   (37)	   and	   the	   cAMP-­‐dependent	   kinase	   PKA	   (38),	   with	   important	   functional	   consequences	   to	  lymphocyte	  activation.	  	  Of	  note,	   although	   the	  different	  pathways	   initiated	  by	  PI3K	  activation	  have	  specific	  targets,	  they	  can	  be	  also	  connected	  to	  reinforce	  others.	  For	  instance,	  PKCθ-­‐mediated	  activation	  of	  IKK/NFκB	  is	  targeted	  in	  a	  PI3-­‐dependent	  manner	  through	  PDK1-­‐,	  mTORC2-­‐	  and	  Tec-­‐dependent	  mechanisms.	  
5.	  CLASS	  I-­‐PI3KINASES:	  RELEVANCE	  TO	  CANCER	  The	   clues	   for	   an	   association	   of	   PI3K	   and	   tumor	   development	   and	   growth	  come	   from	  different	   sources.	  On	  one	  hand,	   some	  oncogenic	   retroviruses	  possess	  genes	   derived	   from	   those	   encoding	   p110α	   and	   AKT.	   On	   the	   other,	   the	  PtdIns(3,4,5)P3	  phosphatase	  PTEN	  is	  a	  tumor	  suppressor	  gene	  frequently	  mutated	  in	   human	   tumors	   with	   the	   consequence	   of	   a	   constitutive	   activation	   of	   the	   PI3K	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pathway.	  Another	  link	  is	  the	  observation	  of	  genomic	  amplification	  of	  genes	  coding	  for	  p110α	  (PIK3CA)	  or	  its	  target	  Akt	  (AKT)	  in	  several	  types	  of	  cancer	  (reviewed	  in	  (39-­‐41)).	  Although	   all	   Class	   I	   PI3K	   subunits	   have	   oncogenic	   potential	   in	   vitro;	   the	  seminal	  work	  by	  Samuels	  et	  al.	  (42),	  later	  confirmed	  by	  abundant	  data,	  shows	  that	  the	  p110α	  catalytic	  isoform	  but	  not	  other	  isoforms	  is	  mutated	  with	  high	  frequency	  in	   colorectal	   and	   other	   different	   human	   cancer	   cells	   (39-­‐41)).	   These	   gain-­‐of	  function	  mutations	  of	  the	  PIK3CA	  gene	  are	  located	  in	  the	  ABD	  and	  C2	  domains	  of	  p110α,	  but	  particularly	  in	  the	  helical	  and	  catalytic	  domains.	  The	  enzymatic	  activity	  is	   increased	   by	   different	   mechanisms	   including	   altered	   interaction	   between	   the	  ABD	   and	   kinase	   domains	   of	   p110α,	   between	   the	   C2	   domain	   and	   the	   p85	   iSH2	  domain,	   between	   the	   p85	   nSH2	   domain	   and	   the	   helical	   and	   kinase	   domains,	   or	  between	   the	   kinase	   domain	   and	   the	   cell	   membrane,	   increasing	   accessibility	   to	  phospholipid	  substrates.	  Mutations	  in	  the	  PIK3R1	  gene	  coding	  the	  p85α	  regulatory	  subunit	  have	  been	  also	  described	  in	  different	  cancer	  cells.	  They	  are	  clustered	  in	  the	  inter-­‐SH2	  domain	  of	  p85	  that	  contacts	  the	  C2	  domain	  of	  catalytic	  subunits	  or	  in	  the	  nSH2	   domain	   that	   interacts	   with	   the	   helical	   domain	   of	   catalytic	   subunits;	   both	  might	   interfere	   inhibitory	   interactions	   between	   subunits.	   Interestingly,	   these	  cancer-­‐derived	   gain-­‐of-­‐function	   mutations	   in	   p85α	   function	   through	   the	   p110α,	  but	   not	   other	   PI3K	   catalytic	   subunits	   (43).	   Last,	   the	   p110α	   isoform	   of	   PI3K	   in	  endothelium	   plays	   a	   role	   in	   tumor	   growth	   through	   its	   contribution	   to	   tumor	  angiogenesis	  (44).	  Gain-­‐of-­‐function	  E1021K	  mutations	  of	  p110δ	   have	  been	   recently	   reported	  in	   a	   residue	   of	   the	   catalytic	   domain	   similar	   to	   those	   found	   in	   p110α,	   but	   these	  mutations	   are	   surprisingly	   associated	   with	   IgM	   hyperglobulinemia	   and	  immunodeficiency	   rather	   than	   cancer	   (45).	   However,	   p110δ	   can	   favour	   tumor	  growth	  by	   several	  documented	  mechanisms.	  Firstly,	   in	   some	  human	  ovarian	  and	  colorectal	  tumors	  PIK3CD	  transcripts	  can	  be	  alternatively	  spliced	  to	  generate	  a	  37	  kDa	   protein	   (p37δ)	   that	   maintains	   the	   ABD	   and	   RBD	   domains	   of	   p110δ.	   This	  protein	  can	  enhance	  the	  proliferation	  and	  invasive	  properties	  of	  transformed	  cells	  (46).	   In	   second	   place,	   p110δ	   activation	   can	   indirectly	   inhibit	   the	   activity	   of	   the	  PTEN	   phosphatase	   by	   a	   mechanism	   involving	   RhoA	   (47).	   Enhanced	   p110δ	  expression	   in	   solid	   tumors	   in	   fact	   suppresses	   PTEN,	   contributing	   to	   cell	   growth	  and	   –likely-­‐	   to	   cancer	   progression	   of	   malignancies	   of	   hematopoietic	   and	   non-­‐hematopoietic	   origin	   (48,49).	   The	   complexity	   of	   PI3Kinase	   activity	   regulation	   is	  further	   highlighted	   by	   the	   ability	   of	   p85α	   to	   bind	   to	   and	   to	   activate	   PTEN	   in	  transformed	  cell	  lines	  (reviewed	  in	  (50)).	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6.	  PI3K	  INHIBITORS	  OF	  BROAD	  AND	  RESTRICTED	  SPECIFICITY.	  IMPORTANCE	  TO	  
CANCER.	  Hence,	  PI3K	  inhibitors,	  or	  inhibitors	  of	  PI3K	  targets	  like	  Akt	  or	  mTOR,	  have	  been	   actively	   looked	   for	   as	   anti-­‐cancer	   drugs	   (see	   (51),	   for	   a	   recent	   review).	   In	  these	   assays	   p110α-­‐,	   p110β-­‐,	   p110δ-­‐,	   p110γ-­‐,	   dual	   p110γ/δ-­‐specific	   or	   pan-­‐PI3K	  inhibitors,	   as	   well	   as	   dual	   PI3K-­‐mTOR	   inhibitors	   are	   under	   investigation	   in	  experimental	  tests	  and	  clinical	  trials.	  	  
7.	  ROLE	  OF	  CLASS	  IA	  AND	  CLASS	  IB	  PI3KINASES	  IN	  THE	  CONTROL	  OF	  IMMUNE	  
RESPONSES.	  GENETIC	  MODELS	  AND	  PI3K	  INHIBITORS	  The	   relevance	  of	   class	   IA	  PI3K-­‐mediated	   signals	   to	   all	   steps	  of	   innate	   and	  adaptive	   immune	   responses	   immediately	   point	   to	   the	   potential	   relevance	   of	  inhibitors	  of	  PI3K	  or	  of	  PI3K	  effectors	  as	  immunomodulators	  and	  therapeutic	  tools	  in	  many	  socially	  relevant	  immune-­‐mediated	  diseases	  (17,18,22,52-­‐56).	  The	  role	  of	  PI3K	   in	   immunity	   has	   been	   analyzed	   in	   vivo	   by	   the	   generation	   of	   mice	   lacking	  specific	   regulatory	   and	   catalytic	   subunits,	   or	   expressing	   kinase-­‐dead	  mutants	   of	  specific	   subunits,	   or	   by	   means	   of	   specific	   inhibitors	   of	   PI3K	   or	   its	   downstream	  signaling	   targets.	   In	   vitro	   the	   analysis	   has	   involved	   cell	   lines	   derived	   from	   the	  above	  models,	   specific	   inhibitors,	   and	   knock-­‐down	   approaches	   using	   siRNA.	  We	  shall	   now	   review	   the	   genetic	   and	   pharmacological	   data	   that	   supports	   this	  immunomodulatory	  potential	  in	  the	  adaptive	  immune	  response	  mediated	  by	  B	  and	  T	  lymphocytes.	  
8.	  CLASS	  IA	  AND	  IB	  PI3K	  IN	  IMMUNITY:	  LESSONS	  FROM	  GENETIC	  STUDIES	  IN	  B	  
LYMPHOCYTES.	  	  B	   lymphocytes	   are	   an	  essential	   arm	  of	   the	   adaptive	   immune	   responses	   as	  the	   cells	   responsible	   of	   antibody	   responses	   against	   pathogens;	   antibodies	   are	  produced	  in	  great	  quantities	  by	  the	  B-­‐cell	  derived	  plasma	  cells.	  The	  quality	  of	  the	  antibodies	   both	   in	   terms	   of	   their	   affinity	   for	   the	   antigen	   and	   the	   class	   of	   the	  constant	   regions	   is	   essential	   to	   efficient	   removal	   of	   parasites,	   and	   is	   largely	  determined	  by	  the	  cytokines	  in	  the	  milieu,	  particularly	  those	  secreted	  by	  antigen-­‐specific	  T	  helper	  cells.	  Mature	  B	   lymphocytes	  exist	   in	   two	  major	  subsets,	  namely	  the	   B-­‐1	   cells	   found	   in	   body	   cavities	   like	   the	   peritoneum	   that	   have	   innate	  properties,	  and	  the	  B-­‐2	  cells	  that	  comprise	  non-­‐recirculating	  MZ	  (marginal	  zone)	  B	  cells	   and	   the	   FO	   (follicular)	   B	   cells	   that	   recirculate	   through	   the	   blood	   and	  secondary	  lymphoid	  organs.	  	  The	  role	  of	   regulatory	  subunits	  has	  been	  analyzed	   in	  pan-­‐p85α-­‐/-­‐	   (p85α-­‐/-­‐,	  p55α-­‐/-­‐,	   p50α-­‐/-­‐)	   defective	   mice,	   lacking	   all	   p85α	   isoforms.	   These	   mice	   have	  perinatal	   lethality,	   assays	   using	   RAG2	   chimeric	   mice	   with	   hematopoietic	   cells	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derived	   from	   mutant	   ES	   cells	   had	   less	   mature	   B	   cells	   and	   low	   serum	  immunoglobulins;	  in	  vitro	  activation	  of	  B	  cells	  was	  also	  impaired	  (57).	  Mice	  lacking	  p85α	   subunits	   but	  not	  p55α	   or	  p50α	   had	   a	   similar	  phenotype;	   both	  phenotypes	  were	  very	  similar	  to	  the	  X-­‐linked	  immunodeficiency	  due	  to	  Bruton	  tyrosine	  kinase	  (Btk)	   deficiency	   (58).	   No	   immunological	   defects	   have	   been	   described	   in	   mice	  lacking	   p55α	   or	   p50α	   subunits	   (59).	   Deletion	   of	   p85β	   produced	   normal	   B	   cell	  responses	   (60).	   Last,	   the	   absence	   of	   p85α	   and/or	   p85β	   reduced	   basal,	   PI3K	  dependent	  lymphocyte	  motility	  of	  B	  lymphocytes	  (61).	  There	  is	  no	  data	  concerning	  the	   effect	   of	   class	   IB	   regulatory	   subunit	   loss	   in	   lymphocyte	   function,	   data	   in	  neutrophils	  indicate	  impaired	  cytokine-­‐driven	  motility	  (62)	  (summarized	  in	  Table	  1).	  
Table	  1.-­‐	  Effect	  of	  Class	   I	  PI3-­‐K	  subunit	  mutations	  and	  defects	   in	  B	  and	  T	   lymphocyte	  phenotype	  and	  function.	  
Subunit	  
	  
Phenotype,	  B	  lymphocyte	  
	  




Class	  IA	  regulatory	   	   	   	  
Pik3r1	  	   	   	   	  pan-­‐p85α-­‐/-­‐	  (p85α-­‐/-­‐,	  p55α-­‐/-­‐,	  p50α-­‐/-­‐)	   Low	  B	  cell	  number;	  impaired	  activation	  and	  motility	   Impaired	  motility	   Perinatal	  lethality	  (57,61).	  p85α-­‐/-­‐	  only	   Impaired	  motility	   Normal	  development,	  reduced	  motility;	  enhanced	  response	  in	  vitro;	  lower	  T-­‐dependent	  secondary	  response	  
(60,61,71)..	  
p55α-­‐/-­‐,	  p50α-­‐/-­‐	  	   Normal	   Normal	   (59).	  	   	   	   	  
Pik3r2	  	   	   	   	  p85β-­‐/-­‐	  	   Impaired	  motility	   Impaired	  motility	   (61)	  p85α-­‐/-­‐,	  p55α-­‐/-­‐,	  p50α-­‐/-­‐;	  	  p85β-­‐/-­‐,	   Impaired	  motility	   Impaired	  motility,	  Th2,	  Treg	  differentiation;	  autoimmune	  syndrome	  	   (61,72,73).	  	   	   	   	  
Pik3r3	  	   	   	   	  p55γ-­‐/-­‐	  	   n.d.	   n.d.	   	  	   	   	   	  
Class	  IB	  regulatory	   	   	   	  
Pik3r5	  	   	   	   	  p101-­‐/-­‐	  	   n.d.	  	   n.d.	   Neutrophil	  migration	  impaired	  (62)	  	   	   	   	  
Pik3r6	  	   	   	   	  p87/84	  	   n.d.	  	   n.d.	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Class	  IA	  catalytic	   	   	   	  
Pik3ca	  	   	   	   	  p110α	  CD2Cre	  (lymphocyte	  specific	  deletion)	   Normal	  development;	  normal	  responses	  in	  vitro	  and	  in	  vivo	  	   n.d.	   (63)	  	   	   	   	  	   	   	   	  
Pik3cb	  	   	   	   	  p110β	  CD2Cre	  (lymphocyte	  specific	  deletion)	   Normal	  	   n.d.	   (63)	  	   	   	   	  	   	   	   	  	   	   	   	  
Pik3cd	  	   	   	   	  p110δ-­‐/-­‐	  	   Impaired	  B	  cell	  homeostasis	  activation	  and	  function	  	   No	  alterations	  detected	   (64,65)	  p110δ	  CD4Cre	  (T	  cell	  specific	  deletion)	   	   Impaired	  Tfh,	  ICOS	  signaling	  	   (74)	  p110δD910A/D910A	  	   Impaired	  B	  cell	  activation	  and	  function,	  enhanced	  IgE	  levels	   Impaired	  T	  cell	  activation	  and	  function,	  inflammatory	  bowel	  disease	   (66-­‐68).	  p110α	  CD2Cre	  lymphocyte	  specific	  deletion;	  p110δD910A/D910A	  	  
p110δ	  or	  p110δ	  signal	  tonic	  BCR	  signaling,	  B	  cell	  development	  and	  survival;	  p110δ	  essential	  in	  agonist	  BCR	  signaling	  	  
n.d.	   (63)	  
	   	   	   	  
Class	  IB	  catalytic	   	   	   	  
Pik3cg	  	   	   	   	  p110γ-­‐/-­‐	  	   B	  cells	  normal	   Altered	  thymocyte	  development,	  impaired	  or	  normal	  activation,	  impaired	  migration	  
(24,69,75-­‐78).	  
p110γ-­‐/-­‐	  p110δ-­‐/-­‐	  	  	  p110γ-­‐/-­‐	  p110δD910A/D910A	   Similar	  to	  p110δ-­‐/-­‐	  or	  p110δD910A/D910A	  	   Blocked	   pre-­‐TCR	   signal,	  severe	  T	  cell	  high	  thymocyte	  apoptosis,	   severe	   T	   cell	  lymphopenia,	   Th2-­‐skewed	  responses,	  high	  IgE	  levels	  	  
(70,79)	  	  
	   The	   study	   of	   the	   effect	   of	   losing	   p110α	   or	   p110β	   on	   lymphocyte	  development	  and	   function	  has	  been	   impaired	  by	   the	  embryonic	  or	  early	   lethality	  after	  birth	  of	  null	  (p110α-­‐/-­‐	  and	  p110β-­‐/-­‐)	  or	  knock-­‐in	  kinase-­‐dead	  (p110αD933A	  and	  p110βK805R)	   mutant	   mice	   (reviewed	   in	   (5)).	   Lymphocyte-­‐specific	   conditional	  deletion	   of	   p110α	   or	   p110β	   in	   floxed	   p110α/CD2-­‐Cre	   or	   floxed	   p110β/CD2-­‐Cre	  mice	   showed	   no	   defect	   in	   B	   lymphocytes	   (63).	   In	   contrast,	   p110δ-­‐/-­‐	   (64,65)	   and	  p110δD910A	   mice	   are	   viable	   and	   have	   defects	   in	   B	   cell	   antigen	   receptor	   (BCR)-­‐induced	  activation	  (63,66).	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In	  p110δ-­‐/-­‐	  mice	  Ig	  in	  serum	  and	  the	  number	  of	  mature	  B	  cells	  were	  low,	  B1	  and	  marginal	  zone	  B	  cells	  were	  defective,	  yet	  T	  cell	  numbers	  and	  responses	  were	  normal.	   Responses	   to	   T-­‐cell	   independent	   antigens	   are	   low	   and	   T-­‐cell	   dependent	  responses	   are	   severely	   impaired.	   B	   cell	   antigen	   receptor	   (BCR)-­‐	   and	   CD40-­‐early	  signals	   like	   calcium	   flux,	   activation	   of	   phospholipase	   C,	   Akt,	   and	   Btk,	   as	   well	   as	  proliferation	  are	  impaired	  (64,65).	  These	  data	  suggested	  a	  specific,	  unique	  role	  for	  p110δ	  in	  B	  cell	  signaling	  and	  function.	  	  The	  results	  obtained	  in	  mice	  in	  which	  wild	  type	  p110δ	  is	  substituted	  by	  the	  catalytically	  inactive	  form	  p110δD910A	  were	  similar	  concerning	  B	  lymphocytes,	  but	  in	   this	   case	   T	   cell	   antigen	   receptor	   (TCR)	   signaling	   was	   also	   impaired;	   mice	  developed	   inflammatory	   bowel	   disease	   (66).	   Furthermore,	   p110δD910A	   mice	   had	  high	   serum	   amounts	   of	   antigen-­‐specific	   IgE	   antibody	   despite	   reduced	   levels	   of	  other	   isotypes	   like	   IgM	   or	   IgG1;	   the	   same	   was	   observed	   in	   antigen-­‐specific	  responses	  or	  using	  p110δ-­‐specific	  inhibitors	  (67).	  This	  is	  due	  to	  the	  specific	  role	  of	  p110δ-­‐mediated	  signals	  in	  maintaining	  high	  levels	  of	  the	  transcription	  repressor	  B	  cell	   lymphoma	   6	   (BCL6)	   acting	   on	   the	   IgE	   promoter	   in	   germinal	   center	   (GC)	   B	  lymphocytes	   (68),	  where	  B	   cells	   actively	   proliferate	   and	   are	   induced	   to	   produce	  antibody	   responses	   of	   even	   higher	   affinity	   under	   the	   guidance	   of	   specialized	  follicular	  helper	  T	  (Tfh)	  cells.	  Later	  work	  by	  the	  group	  of	  B.	  Alarcón	  has	  shown	  that,	  indeed	  p110δ	  stably	  binds	   to	   BCR	   and	   TCR	   ITAM	   containing	   chains	   through	   the	   Ras	   family	   protein	  RRas2	   (TC21)	   actively	  participating	   in	   tonic	   and	   ligand	  activation	   signaling	   (15).	  Paradoxically,	  recent	  data	  show	  that	  patients	  with	  a	  spontaneous	  dominant	  gain-­‐of-­‐function	   mutation	   of	   p110δ	   (p110δE1021K)	   suffer	   primary	   immunodeficiency	  with	  low	  IgG2	  serum	  levels,	  deficient	  responses	  to	  vaccines,	  lymphopenia	  and	  high	  sensitivity	   to	   activation-­‐induced	   cell	   death,	   despite	   elevated	   levels	   of	  PtdIns(3,4,5)P3	  and	  phosphorylated	  Akt	  (45).	  Intriguingly,	   mice	   with	   double	   lymphocyte	   deletion	   of	   p110α	   and	  p110δD910A	  indicates	  that	  p110α	  could	  substitute	  for	  p110δ	  in	  agonist-­‐independent	  tonic	  BCR	  signaling	  necessary	  for	  B	  cell	  development	  from	  B	  cell	  progenitors	  and	  B	  cell	   survival;	   however	   p110α	   could	   not	   substitute	   for	   p110δ	   in	   agonist	   BCR	  activation	  (63).	  Both	   p110δ	   and	   p110γ	   catalytic	   subunits	   are	   highly	   expressed	   in	  lymphocytes	   but	   not	   in	   other	   cell	   types	   that	   are	   not	   of	   hematopoietic	   origin.	  However,	  mice	  p110γ−/−	  had	  no	  B	  cell	  defects	  but	  show	  altered	  differentiation	  in	  the	  thymus,	  with	  decreased	  CD4+	  numbers,	  impaired	  migration	  and	  survival	  of	  mature	  thymocyte	  as	  well	   as	  mature	  T	  cell	   activation,	   (69).	  Mice	  deficient	   in	  both	  p110γ	  and	  p110δ	   (p110γ-­‐/-­‐	   p110δD910A)	   have	   a	  B	   cell	   phenotype	   similar	   to	   that	   of	   their	  p110γ-­‐sufficient	  counterparts	  (70).	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9.	   CLASS	   IA	   AND	   IB	   IN	   IMMUNITY:	   LESSONS	   FROM	   GENETIC	   STUDIES:	   T	  
LYMPHOCYTES.	  	  In	   mice	   with	   hematopoietic	   cells	   lacking	   all	   p85α-­‐/-­‐,	   p55α-­‐/-­‐,	   p50α-­‐/-­‐	  subunits	   the	   number	   and	   in	   vitro	   activation	   of	   T	   cells	   was	   largely	   normal	   (57);	  mice	   lacking	  p85α	   subunits	  but	  not	  p55α	  or	  p50α	  had	  a	  similar	  phenotype	  (58).	  No	   immunological	   defects	   have	   been	   described	   in	   mice	   lacking	   p55α	   or	   p50α	  subunits	   (59).	  Deletion	  of	  p85β	   induced	  enhanced	  T-­‐lymphocyte	   responses	   (60),	  however	   loss	  of	  p85β	   impaired	  secondary	  T	  cell	  dependent	  antigen	  responses	  by	  CD28-­‐mediated	  mechanisms	   (71).	   Conditional	   deletion	  of	   the	   class	   IA	   regulatory	  subunits	  p85α,	  p55α,	  p50α,	  and	  p85β	  in	  the	  T	  cell	  lineage	  (p55γ	  is	  undetectable	  in	  T	   lymphocytes,	   J.M.R.,	   unpublished	   data)	   resulted	   in	   normal	   T	   cell	   development	  and	   Th1	   differentiation.	   PI3K	   signals,	   antibody	   responses	   to	   T-­‐cell	   dependent	  antigens,	   Th2,	   and	   Treg	   differentiation	   were	   impaired	   and	   the	   animals	   could	  develop	  an	  autoimmune	  Sjögren’s-­‐like	  syndrome	  (72,73).	  As	  in	  B	  lymphocytes,	  loss	  of	  p85α	  and	  p85β	  reduced	  basal	  lymphocyte	  motility	  (61).	  In	  p110δ-­‐/-­‐	  mice	  the	  number	  of	  quality	  of	  T	  lymphocytes	  appear	  normal;	  and	  decreased	  responses	  to	  T-­‐cell	  dependent	  antibody	  responses	  might	  be	  largely	  due	  to	   defects	   in	   the	   B	   cell	   compartment	   (64,65).	   Mice	   where	   wild	   type	   p110δ	   is	  substituted	  by	  the	  catalytically	  inactive	  form	  p110δD910A	  were	  similar	  concerning	  B	  lymphocytes,	   but	   in	   this	   case	   T	   cell	   antigen	   receptor	   (TCR)	   signaling	   was	   also	  impaired;	  mice	  developed	  inflammatory	  bowel	  disease	  (66).	  Later	  work	  has	  shown	  that	   the	   p110δ	   subunit	   was	   key	   to	   ICOS-­‐mediated	   costimulation	   of	   effector	  function	  in	  follicular	  helper	  T	  cells	  (74)	  Mice	   with	   deleted	   p110γ	   subunits	   show	   altered	   differentiation	   in	   the	  thymus,	  with	  decreased	  CD4+	  numbers,	  impaired	  migration	  and	  survival	  of	  mature	  thymocyte	  as	  well	  as	  mature	  T	  cell	  activation	  (69,75)	  possibly	  because	  p110γ	  binds	  to	   and	   is	   activated	   by	   TCR	   ligation	   (24).	   However,	   other	   groups	   have	   found	   no	  defects	   in	   CD4+	   T	   cell	   signaling	   and	   proliferation	   but	   did	   show	   strong	   defects	   in	  migration	   and	   trafficking	   in	   TCR	   transgenic	   mice	   (76,77);	   Martin	   et	   al.	   (78)	  observed	  no	  effect	  in	  the	  migration	  and	  trafficking	  of	  naive	  CD8+	  T	  cells,	  or	  in	  their	  proliferation	   and	   activation	   migration.	   In	   contrast,	   migration	   of	   p110γ-­‐deficient	  CD8+	  effector	  T	  cells	  induced	  by	  inflammatory	  stimuli	  was	  impaired	  (78).	  	  Double	   knockout	   mice	   (p110γ-­‐/-­‐p110δ-­‐/-­‐)	   deficient	   for	   both	   p110γ	   and	  p110δ	  have	  severe	  defects	  in	  T	  cell	  differentiation	  as	  thymocytes	  are	  blocked	  in	  the	  DN3-­‐DN4	  selection	  checkpoint	  of	  pre-­‐TCR	  signaling,	  with	  low	  thymocyte	  numbers	  and	   high	   apoptosis	   (79).	  Mice	   lacking	   p110γ	   and	   expressing	   the	   inactive	  mutant	  p110δD910A	   (p110γ-­‐/-­‐	   p110δD910A)	   have	   similarly	   strong	   defects	   in	   thymus	  differentiation,	   but	   the	   few	   remaining	   T	   cells	   infiltrate	   the	   mucosas,	   show	   Th2-­‐skewed	  responses	  and	  anomalously	  high	  IgE	  levels	  (70).	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What	  is	  perhaps	  more	  surprising	  of	  the	  results	  using	  genetic	  models,	  is	  the	  certain	  selectivity	  of	  PI3K	  subunits	   in	  terms	  of	  the	   lymphocyte	  population(s)	  and	  processes	  affected.	  This	  applies	  not	  only	  to	  PI3K	  subunits,	  but	  also	  to	  other	  protein	  targets	  of	  PI3K,	  giving	  clues	  as	  to	  the	  possibility	  of	  selective	  immune	  intervention	  using	   PI3K	   inhibitors	   or	   its	   downstream	   effector	   molecules	   in	   autoimmune	  diseases	   or	   other	   immune-­‐based	   illnesses.	   The	   importance	   of	   PI3K	   in	   different	  types	   of	   cancer	   has	   boosted	   a	   very	   active	   search	   for	   small	   pharmacological	  inhibitors	   directed	   at	   one	   or	   several	   PI3K	   subunits	   and/or	   PI3K	   downstream	  targets	   like	   Akt	   or	   mTOR.	   These	   inhibitors	   have	   the	   potential	   of	   being	   used	   to	  modulate	   immune	   responses.	   The	   use	   of	   inhibitors,	   though,	   has	   to	   take	   into	  account	   the	  harming	  potential	   to	   the	  host,	  particularly	   in	   long-­‐term	   treatment	  of	  chronic	   diseases.	   These	   adverse	   effects	   can	   be	   due	   to	   off-­‐target	   effects	   of	   a	  particular	   drug,	   but	   also	   to	   on-­‐target	   effects	   of	   inhibitors	   of	   widely	   distributed	  enzymes	   fulfilling	   essential	   functions,	   as	   are	  PI3Ks.	  However,	   pre-­‐clinical	  models	  and	   clinical	   trials	   in	   cancer	   indicate	   that	   treatments	  with	   PI3K	   inhibitors	   can	   be	  well	   tolerated,	   even	   when	   using	   inhibitors	   of	   the	   widely	   expressed	   p110α	   and	  p110β,	   or	   even	  pan-­‐class	   I	   PI3K	   inhibitors	   (51).	  Another	   aspect	   to	  be	   taken	   into	  account	  is	  that,	  like	  any	  other	  immunosuppressive	  drug,	  PI3K	  inhibitors	  are	  likely	  to	  have	  undesired	  side	  effects	  including	  increased	  susceptibility	  to	  infection	  (4).	  	  
10.	  CLASS	  IA	  AND	  IB	  PI3K	  IN	  IMMUNITY:	  LESSONS	  FROM	  SPECIFIC	  INHIBITORS	  
IN	  B	  LYMPHOCYTE	  FUNCTION	  As	  mentioned	  before,	  genetic	  defects	  in	  p110δ	  affect	  particularly	  B-­‐1	  and	  B-­‐2	  marginal	  zone	  B	   lymphocytes;	   the	  similarity	  of	   these	  defects	  and	  those	  of	  mice	  lacking	  Akt	  or	   the	  PI3K-­‐recruiting	  costimulatory	  molecule	  CD19	  might	   indicate	  a	  role	   of	   a	   CD19/p110δ	   PI3K/	   Akt/	   Foxo1	   downstream	   signal	   in	   B-­‐1	   and	  MZ	   B-­‐2	  differentiation	  (reviewed	  in	  (22)).	  Using	  the	  p110δ	   inhibitor	  IC87114,	  Bilancio	  et	  al.	  (80)	  found	  strong	  inhibition	  of	  anti-­‐BCR-­‐induced	  proliferation	  of	  B	  lymphocytes,	  Ca2+	   flux,	   or	   phosphorylation	   of	   downstream	   targets	   like	   Akt,	   or	   the	   Akt	   targets	  forkhead	  transcription	  factor/forkhead	  box	  O3a	  (FOXO3a),	  and	  p70	  S6	  kinase	  (p70	  S6K),	   and	   partial	   inhibition	   of	   extracellular	   signal-­‐regulated	   kinase	   (Erk),	   that	  mimicked	   p110δ	   defects.	   In	   contrast,	   the	   p110γ/α	   inhibitor	   AS-­‐604850	   had	   no	  detectable	  effect	  on	  these	  parameters	  (80).	  Despite	  the	  fact	  that	  p110δ,	  rather	  than	  p110α	   catalytic	   subunits	   of	   PI3K,	   had	  detectable	   effects	   in	  B	   lymphocytes	   and	  B	  cell	  responses,	  and	  p110δ	  binds	  to	  the	  BCR	  (15),	  So	  et	  al.	  recently	  analyzed	  highly	  specific	  p110α	   inhibitors	  to	  assess	  a	  possible	  role	  for	  the	  p110α-­‐subunit	  in	  B	  cell	  function	  (81).	  They	  observed	  a	  minor	  but	  clear	  effect	  of	  p110α-­‐specific	  inhibitors	  A66	   and	   MLN1117	   on	   early	   Akt	   activation	   and	   Ca2+	   flux,	   or	   B	   cell	   proliferation	  induced	  by	  BCR	  stimuli	  in	  vitro,	  but	  not	  by	  cytokines	  IL-­‐4	  or	  BAFF.	  This	  inhibition	  
Class	  I	  phosphoinositide	  3-­‐kinases	  in	  immunity…	  	  
	  107	  	  
could	  add	  to	  the	  stronger	  inhibition	  induced	  by	  the	  p110δ	  inhibitor	  IC87114	  on	  the	  same	  phenomena,	  that	  was	  not	  complete	  (81).	  	  
In	  vivo,	  unlike	  administration	  of	  MLN1117,	  daily	  administration	  of	  a	  p110δ	  (IC87114)	   or	   a	   pan-­‐PI3K	   inhibitor	   (GDC-­‐0941)	   to	   immunized	   mice	   strongly	  reduced	  marginal	  zone	  B	  cell	  numbers	   in	   the	  spleen;	  GDC-­‐0941	  also	  reduced	   the	  number	  of	  germinal	  centers	  (81).	  Despite	  these	  effects,	  antigen	  specific	  IgM,	  IgG1	  titers	   in	   the	   serum	   of	   immunized	   mice	   was	   not	   significantly	   lower	   or	   were	  elevated,	  and	  in	  fact	  IgE	  titers	  were	  significantly	  enhanced	  by	  the	  p110δ	  inhibitor	  IC87114	   or	   the	   pan-­‐PI3K	   inhibitor	   GDC-­‐0941,	   but	   not	   by	   p110α	   inhibitors	   (81).	  Our	   own	   results	  with	   a	   dual	   p110α/δ	   inhibitor	   (ETP-­‐46321)	   administered	   after	  initiation	  of	   antigen	   responses	   showed	   inhibition	  of	   antigen-­‐specific	   serum	   IgG3,	  but	  not	  of	  IgM,	  IgG1,	  or	  IgG2b	  antibody	  (82).	  As	  mentioned	   above,	   p110α	   inhibition	  did	  not	   affect	  B	   cell	  Akt	   and	  FOXO	  signaling	  or	  survival	  induced	  by	  cytokines	  like	  IL-­‐4	  or	  BAFF,	  yet	  p110δ	  inhibitors,	  pan-­‐PI3K	   inhibitors,	   and	   to	   a	   lesser	   extent,	   also	   p110β	   inhibitors	   like	   TGX-­‐221	  produced	  significant	  results	  (80,81).	  It	  has	  been	  observed	  that	  p110δ	  signals	  play	  an	  essential	  role	  in	  inhibiting	  excess	   IgE	   production	   by	   maintaining	   the	   levels	   of	   the	   BCL6	   that	   negatively	  controls	   the	   IgG1	   to	   IgE	  switch.	  These	  effects	  can	  be	  mimicked	   in	  vitro	  or	   in	  vivo	  using	   p110δ-­‐specific	   inhibitors	   like	   IC87114,	   or	   broad-­‐spectrum	   PI3K	   inhibitors	  like	  PIK-­‐90	  and	  PI-­‐103,	  or	  GDC-­‐0941,	  but	  not	  by	  	  p110α	   inhibitors	  like	  MLN1117	  (67,68,81).	  
11.	  CLASS	  IA	  AND	  IB	  PI3K	  IN	  IMMUNITY:	  LESSONS	  FROM	  SPECIFIC	  INHIBITORS	  
IN	  T	  LYMPHOCYTES	  Early	  data	  by	  Shi	  et	  al.	  using	  the	  PI3K	  inhibitor	  Wortmannin	  indicated	  that	  the	  role	  of	  PI3K	  in	  (CD4+)	  T	  lymphocyte	  activation	  was	  dependent	  on	  the	  stimulus	  used.	   Production	   of	   IL-­‐2	   by	   the	   surrogate	   antigen	   activation	   anti-­‐CD3	   antibodies	  plus	   CD28	   costimulus	   seemed	   largely	   PI3K-­‐independent,	  whereas	   activation	   and	  Th2	   differentiation	   of	   the	   same	   cells	   by	   peptide	   antigen	   and	   antigen-­‐presenting	  cells	   was	   clearly	   inhibited	   by	   Wortmannin	   (83).	   Although	   the	   specificity	   of	  Wortmannin	   for	   PI3K	   has	   been	   questioned	   (see,	   i.e.	   (9,84)),	   later	   studies	   by	  Okkenhaugh	   et	   al.	   in	  mice	   expressing	   the	   inactive	   p110δD910A	  mutant	   also	   found	  that	   antigen	   activation,	   rather	   that	   activation	   by	   anti-­‐CD3	   plus	   anti-­‐CD28,	   was	  impaired	   in	   the	   mutant	   mice(66,85).	   Furthermore,	   differentiation	   of	   p110δD910A	  CD4+	   T	   lymphocyte	   into	   the	   Th1	   (IFN-­‐γ-­‐producing)	   and	   Th2	   (IL-­‐4-­‐producing)	   T	  helper	  cell	  subsets	  was	  also	  impaired.	  The	  p110δ	  inhibitor	  IC87114	  inhibited	  Th1	  differentiation,	  but	  Th17	  differentiation	  was	  even	  more	  sensitive	  to	  inhibition	  (86).	  In	  contrast,	  we	  found	  that	  in	  cultures	  of	  naive	  CD4+	  T	  lymphocytes	  activated	  with	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anti-­‐CD3	  plus	  anti-­‐CD28	  antibodies	  under	  neutral	  conditions	  IFN-­‐γ-­‐production	  was	  highly	  sensitive	  to	  inhibition	  of	  PI3K,	  at	  doses	  ten-­‐fold	  lower	  than	  those	  needed	  to	  inhibit	   proliferation,	   IL-­‐2,	   or	   IL-­‐10.	   The	   p110δ	   inhibitor	   IC87114	   or	   the	   dual	  p110α/δ	   inhibitor	   ETP-­‐46321,	  were	   particularly	   effective,	  whereas	   inhibition	   by	  A66,	  a	  p110α	   inhibitor	  was	  not	  as	  marked	  (82).	  A	  differentially	  high	  inhibition	  of	  IC87114	   on	   IFN-­‐γ	   production	   versus	   proliferation	   was	   also	   observed	   by	  Okkenhaugh’s	   group	   (87).	   Furthermore,	   these	   authors	   observed	   that	   isolated	  memory/effector	   cells	   were	  more	   sensitive	   to	   the	   p110δ	   inhibitor	   IC87114	   that	  naive	  cells.	  These	  results	  paved	  the	  way	  to	  show	  inhibition	  by	  IC87114	  of	  anti-­‐CD3	  antibody-­‐mediated	  T	  cell	  activation	  or	  recall	  responses	  to	  vaccines	  in	  human	  cells	  (87).	   In	   our	   experience,	   though,	   inhibition	   of	   cytokine	   production	   by	   CD4+	   blast	  cells	  activation	  with	  anti-­‐CD3	  or	  anti-­‐CD3	  plus	  anti-­‐ICOS	  antibodies	  was	  similar	  to	  that	  observed	  in	  activation	  of	  naive	  CD4+	  T	  cells	  (82).	  In	   contrast,	   So	   et	   al.	   observed	  no	   significant	   effect	   of	   p110α	   inhibition	  by	  A66	   or	   MLN1117	   on	   antigen-­‐	   or	   mitogen-­‐	   induced	   CD4+	   T	   cell	   proliferation,	   or	  secretion	   of	   IL-­‐2	   and	   IFN-­‐γ,	   although	   there	   was	   some	   inhibition	   of	   Akt	  phosphorylation,	   and	   p110α	   inhibitors	   enhanced	   the	   clear	   but	   not	   complete	  inhibition	   induced	   by	   IC87114	   (81).	   A	   contribution	   of	   p110α	   to	   TCR	   and	  costimulation	  signaling	  is	  also	  suggested	  in	  the	  response	  of	  the	  CD4+	  T	  cell	  line	  D10	  to	   anti-­‐CD3	   and	   anti-­‐ICOS	   (14).	   In	   this	   system,	  we	   observed	  partial	   inhibition	   of	  early	   Akt	   phosphorylation	   by	   the	   p110α	   inhibitor	   PIK-­‐75	   or	   by	   p110α	   silencing	  (14).	   Intriguingly,	   whereas	   silencing	   p110δ	   or	   inhibition	   with	   IC87114	   clearly	  inhibited	   both	   Akt	   and	   Erk	   activation,	   p110α	   silencing	   markedly	   enhanced	   Erk	  phosphorylation,	  suggesting	  that	  p110α	  might	  exert	  a	  negative	  control	  over	  some	  p110δ	  signals	  (14).	  	  Follicular	   helper	   T	   cells	   (Tfh)	   are	   particularly	   and	   functionally	   very	  important	   to	   the	   development	   germinal	   centers	   and	   of	   efficient	   antibody	  responses,	  promoting	  antibody	  affinity	  maturation	  and	  differentiation	  of	  memory	  cells.	  They	  characteristically	  express	  the	  surface	  molecules	  CXCR5,	  PD-­‐1	  and	  ICOS,	  as	   well	   as	   the	   transcription	   suppressor	   Bcl6	   (88).	   Although	   Tfh	   cells	   able	   of	  producing	  different	  antibody-­‐promoting	  cytokines	  (IL-­‐4,	  IL-­‐10,	  IL-­‐17,	  or	  IFN-­‐γ)	  can	  be	  found	  in	  vivo,	  IL-­‐21	  is	  the	  most	  characteristic	  cytokine	  of	  Tfh	  cells.	  Signaling	  by	  the	   PI3K-­‐binding	   costimulators	   CD28	   and	   ICOS	   are	   needed	   for	   efficient	  development	   of	   Tfh	   and	   germinal	   centers.	   Work	   with	   mice	   expressing	   ICOS	  mutants	  unable	  to	  bind	  PI3K,	  or	  in	  mice	  expressing	  the	  inactive	  p110δD910A	  kinase,	  or	  inhibition	  with	  the	  p110δ	   inhibitor	  IC87114,	  taken	  together	  indicate	  that	  PI3K	  p110δ	   is	   needed	   for	   Tfh	   differentiation	   and	   antibody	   production	   in	   a	   ICOS	  dependent	  way;	   early	   TCR	   signaling	   or	   IL-­‐21	   production	   in	   differentiated	   Tfh	   is	  also	  potentiated	  by	  ICOS	  signaling	  and	  inhibited	  by	  IC87114	  (74,89).	  So	  et	  al.	  have	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recently	   described	   that	   IC87114	   but	   not	   the	   p110α	   inhibitor	   MLN1117	   inhibits	  germinal	  center	  formation	  (81).	  Our	  own	  data	  indicates	  that	  ICOS	  enhances	  early	  TCR	  activating	  signals	  and	  IL-­‐17A	  production	  in	  Tfh	  in	  a	  p110δ-­‐dependent	  fashion,	  yet	  IL-­‐21	  secretion	  is	  largely	  independent	  of	  ICOS	  and	  inhibition	  of	  both	  p110δ	  and	  p110α	  is	  needed	  to	  block	  IL-­‐21	  production	  (82).	  ICOS	   and	   its	   PI3K	   associated	   activity	   intervene	   in	   yet	   another	   aspect	   of	  germinal	  center	  development,	  namely	  in	  the	  recruitment	  of	  activated	  T	  helper	  cells	  into	   the	   follicle.	   ICOS	   is	   directly	   involved	   in	   this	   movement,	   but	   this	   effect	   is	  independent	  on	  costimulation,	  yet	  is	  dictated	  by	  the	  interaction	  of	  ICOS	  in	  T	  cells	  and	  its	   ligand	  ICOS-­‐L	  expressed	  in	  bystander	  B	  lymphocytes	  in	  a	  PI3K-­‐dependent	  fashion	  (90).	  ICOS	  ligation,	  as	  ligation	  of	  other	  CD28	  family	  members	  (CD28,	  CTLA-­‐4/CD152)	   can	   induce	   antigen-­‐independent,	   tyrosine	   kinase	   and	   PI3K-­‐dependent	  changes	   in	   actin	   cytoskeleton	   and	   cell	   elongation	   and	   spreading	   (14,91-­‐95).	  However,	  Xu	  et	  al.	  found	  that	  recruitment	  of	  T	  cells	  into	  follicles	  was	  dependent	  on	  the	  p110δ	  PI3K	  subunit	  (90),	  whereas	  using	  a	  Th2	  T	  helper	  cell	  line	  we	  have	  found	  that	  cell	  elongation	  was	  dependent	  on	  p110α,	  rather	  than	  p110δ	  (14).	  Another	   functionally	   important	   T	   cells	   are	   the	   CD4+	   regulatory	   T	   (Treg)	  cells	   that	   express	   the	   transcription	   factor	   Foxp3	   and	  negatively	   control	   adaptive	  immune	   responses,	   as	   they	   expand	   during	   normal	   antigen	   responses	   to	   help	   in	  their	  termination.	  They	  can	  differentiate	  from	  immature	  precursors	  in	  the	  thymus	  (tTreg	   cells),	   but	   also	   from	   mature	   CD4+	   lymphocytes	   in	   the	   periphery	   (pTreg	  cells).	  A	  role	  for	  p110δ	  in	  Treg	  function	  is	  suggested	  by	  data	  from	  mice	  transgenic	  for	   the	   kinase-­‐dead	   p110δD910A	   mutation.	   These	   mice	   have	   reduced	   numbers	   of	  Treg	   cells	   with	   reduced	   suppressor	   capability	   in	   vitro	   and	   in	   vivo	   (96).	  Paradoxically,	   this	   deficit	   in	   Treg	   function	   can	   help	   in	   producing	   efficient	   anti-­‐parasite	  responses	  in	  certain	  cases.	  Unlike	  wild	  type	  mice,	  animals	   lacking	  p110δ	  can	  efficiently	  clear	  Leishmania	  infection	  because	  of	  strong	  defects	  in	  Treg	  number	  and	  homing	  (97).	  It	  is	  also	  paradoxical	  that	  the	  proportion	  of	  Treg	  differentiated	  in	  vitro	  (iTreg)	  can	  be	  fostered	  by	  inhibitors	  of	  PI3K	  or	  mTOR,	  yet	  this	  is	  mainly	  due	  to	  p110α,	  as	  judged	  by	  the	  effect	  of	  inhibitors	  of	  p110α,	  p110β	  or	  p110δ	  (98,99).	  In	   contrast,	   IL-­‐2	   dependent	   PI3K	   signals	   are	   necessary	   for	   Treg	   expansion,	   and	  high	  PI3K	  signals	  due	  to	  PTEN	  deficiency	  do	  not	  affect	  Treg	  function	  in	  vitro	  or	  in	  
vivo	  (100).	  The	   last	   T	   cell	   subset	   to	   be	   considered	   is	   the	   cytotoxic,	   MHC	   class	   I-­‐restricted	  CD8+	  population	  of	  T	  lymphocytes	  that	  has	  a	  prime	  role	  in	  the	  response	  against	   intracellular	   pathogens	   like	   viruses	   as	   well	   as	   in	   anti-­‐tumor	   responses.	  There	  are	  conflicting	  data	  on	  the	  role	  of	  PI3K	  in	  TCR-­‐mediated	  activation	  in	  CD8+	  T	  cells.	  According	  to	  Ni	  et	  al.,	  proliferation	  and	  induction	  of	  cytotoxic	  activity	  induced	  by	  TCR/CD3	  and	  CD28	  ligands	  was	  not	  affected	  by	  the	  PI3K	  inhibitor	  Wortmannin	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(101).	   In	   contrast,	   Phu	   et	   al.	   observed	   clear	   inhibition	   of	   anti-­‐CD3-­‐induced	  proliferation	   and	   cytotoxic	   function	   in	   CD8+	   T	   lymphocytes	   cultured	   in	   the	  presence	  of	  Wortmannin	  or	  LY294002	  (102).	  More	  recently,	  Soond	  et	  al.	   found	  a	  clear	   inhibition	  by	  LY294002	  or	  the	  p110δ	   inhibitor	  IC87114	  on	  antigen-­‐induced	  proliferation	  or	   IL-­‐2	  production	   in	  CD8+	  T	   lymphocytes;	   inhibition	  was	   complete	  when	   IFN-­‐γ	   was	   analyzed.	   D.	   Cantrell’s	   group	   has	   recently	   analyzed	   the	   role	   of	  PI3K	   in	   IL-­‐2-­‐induced	   expansion	   of	   previously	   activated	   CD8+	   T	   lymphocytes.	  Interestingly,	   although	   IL-­‐2	   activated	   PI3K-­‐dependent	   activation	   of	   Akt	  phosphorylation	   in	   these	   cells,	   inhibitors	   of	   PI3K	   like	   IC87114	   blocked	   IL-­‐2-­‐dependent	  Akt	  phosphorylation	  but	  not	  CD8+	  proliferation,	  that	  was	  dependent	  on	  PDK1	   (103).	   Still,	   blocking	   p110δ	   or	   Akt	   enhanced	   the	   expression	   of	   molecules	  involved	   in	   lymph	   node	   homing	   and	   homing	   itself,	   showing	   their	  immunomodulatory	  potential	  in	  these	  cells.	  
12.	  PI3K	  IN	  PATHOLOGICAL	  IMMUNE	  RESPONSES	  Given	  the	  relevant	  role	  of	  PI3K	  in	  immune	  responses,	  particularly	  the	  p110γ	  and	  p110δ	  of	  high	  expression	  in	  leukocytes,	  there	  has	  been	  an	  obvious	  interest	  in	  analyzing	   the	  possible	  use	  of	  PI3K	   inhibitors	   in	  both	  organ-­‐specific	  and	  systemic	  autoimmune	   diseases	   of	   social	   impact	   including	   rheumatoid	   arthritis,	   systemic	  lupus	   erythematosus,	   multiple	   sclerosis,	   or	   its	   animal	   experimental	   models.	  Although	  we	  shall	  focus	  on	  the	  role	  of	  adaptive	  immune	  response	  in	  these	  diseases,	  it	  is	  important	  to	  remember	  that	  PI3K	  have	  an	  essential	  role	  in	  the	  function	  of	  cells	  of	   the	   innate	   arm	   of	   immunity	   like	   macrophages	   and	   dendritic	   cells,	  polymorphonuclear	  leukocytes,	  mast	  cells,	  or	  natural	  killer	  (NK)	  lymphocytes	  (52).	  So,	  the	  ultimate	  effect	  of	  PI3K	  inhibitors	   in	  immune	  responses	   in	  vivo	  will	   largely	  depend	   on	   their	   joint	   effects	   on	   the	   development,	   expansion,	   mobility,	   and	  activation	  of	  effector	  function	  in	  innate	  and	  adaptive	  immunity	  elements.	  
12.a.	  Rheumatoid	  arthritis.	  	  Rheumatoid	  arthritis	  (RA)	  affects	  a	  significant	  fraction	  of	  the	  population.	  It	  is	   an	   immune-­‐mediated,	   chronic	   inflammatory	   disease	   of	   the	   joints	   that	   are	  infiltrated	   by	   leukocytes.	   This	   eventually	   leads	   to	   the	   formation	   of	   pannus,	   the	  damage	   of	   cartilage	   and	   bone	   erosion.	   From	   many	   data,	   including	   those	   from	  animal	   experimental	   models	   it	   is	   assumed	   that	   in	   the	   development	   of	   arthritis	  participate	   immune	   response	   cellular	   elements	   from	   both	   the	   innate	  (macrophages,	   neutrophils,	   mast	   cells)	   and	   adaptive	   (T	   and	   B	   lympocytes)	  immunity.	  	  Data	  from	  mice	  lacking	  p110γ	  catalytic	  subunits	  indicate	  that	  these	  mice	  are	  resistant	  to	  the	  development	  of	  clinical	  symptoms	  of	  arthritis.	  Oral	  administration	  of	  the	  p110γ	  inhibitor	  AS-­‐605240	  ameliorated	  the	  symptoms	  in	  two	  experimental	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models	   of	   arthritis,	   the	   collagen-­‐induced	   arthritis	   (CIA)	   dependent	   on	   T-­‐cell	  dependent	   cytokines	   and	   B	   cell	   help,	   and	   in	   the	   neutrophil-­‐dependent	   arthritis	  induced	  by	  anti-­‐collagen	  II	  monoclonal	  antibodies	  (104).	  Similarly,	  in	  a	  neutrophil-­‐dependent	  model	  of	  arthritis	  induced	  by	  serum	  from	  arthritis	  K/BxN	  mice,	  clinical	  symptoms	   were	   dependent	   on	   p110δ	   and	   p110γ,	   and	   IC87114	   inhibited	  progression	   of	   the	   disease	   (105).	   In	   the	   rat	  model	   of	   adjuvant-­‐induced	   arthritis	  (AIA),	   therapeutic	  oral	   administration	  of	   the	  wide	   spectrum	  phosphatidylinositol	  3-­‐kinase	  inhibitor	  ZSTK474	  ameliorated	  clinical	  signs	  of	  the	  disease	  and	  inhibited	  the	  production	  of	  the	  effector	  cytokines	  IFN-­‐γ	  and	  IL-­‐17	  by	  T	  cells	   in	  vitro,	  or	  the	  proliferation	   and	   prostaglandin	   E2	   (PGE2)	   production	   by	   fibroblast-­‐like	  synoviocytes	  cells	  (FLS)	  (106).	  PI3Kγ	  deficiency	  in	  a	  model	  of	  arthritis	  induced	  by	  transgenic	   expression	   of	   human	   TNF	   reduced	   metalloproteinase	   secretion	   by	  fibroblasts,	   cartilage	   damage	   and	   clinical	   score,	   yet	   did	   not	   affect	   recruitment	   of	  inflammatory	   leukocytes	   (107).	   The	   p110γ-­‐specific	   inhibitor	   AS252424	   also	  inhibited	  invasiveness	  and	  matrix	  metalloproteinase	  secretion	  by	  human	  synovial	  fibroblasts	   from	  patients	  with	  RA.	   Intriguingly,	   in	   FLS	   from	   rheumatoid	   arthritis	  patiens	   PI3K	   p110d	   was	   specifically	   induced	   in	   FLS	   from	   rheumatoid	   arthritis	  patients	   by	   pro-­‐inflammatory	   cytokines	   like	   tumor	   necrosis	   factor	   (TNF),	   TNF	  signaling	  as	  well	  as	  platelet-­‐derived	  growth	  factor	  (PDGF)-­‐dependent	  synoviocyte	  growth	  were	   inhibited	  by	  PI3K	  p110δ	   inhibitors	  CAL-­‐101	  or	   INK007,	   but	  not	  by	  p110α	  inhibitors	  like	  A66	  (108).	  
12.b.	  Systemic	  Lupus	  Erythematosus.	  	  Systemic	   Lupus	   Erythematosus	   (SLE)	   is	   an	   autoimmune,	   chronic,	  inflammatory,	  multisystemic	  disease	  with	  a	  particularly	  high	  incidence	  in	  females.	  SLE	  is	  due	  to	  tissue	  and	  cell	  damage	  induced	  by	  autoantibodies	  generated	  by	  early	  expansion	  of	  long-­‐lived	  autoreactive	  T	  helper	  memory	  cells	  that	  trigger	  polyclonal	  hyperactivity	   of	   B	   lymphocyte	   responses	   and	   hypergammaglobulinemia;	  expansion	  of	  autoreactive	  B	  cells	   leads	  to	  enhanced	   levels	  of	  antibodies	  against	  a	  variety	   of	   self	   antigens,	   particularly	   nuclear	   antigens	   and	   DNA.	   Accumulation	   of	  immune	  complexes	  in	  the	  kidney	  leads	  to	  inflammatory	  reaction	  ultimately	  leading	  to	  glomerulonephritis.	  	  There	   are	   different	   animal	   models	   that	   spontaneously	   develop	   a	   SLE-­‐syndrome,	  including	  the	  widely	  used	  MRL-­‐lpr	  and	  MRL-­‐gld	  mice	  with	  a	  mutation	  in	  the	  expression	  of	   the	  apoptosis-­‐signaling	  Fas	  molecule	  or	   its	   ligand,	   respectively.	  
Roquinsan/san	   mice	   have	   a	   mutation	   that	   produce	   disregulated	   expression	   of	   the	  PI3K	  binding	  costimulatory	  molecule	  ICOS,	  show	  progressively	  enhanced	  numbers	  of	   Tfh,	   of	   germinal	   centers	   and	   autoantibodies,	   and	   nephritis	   (109,110)	   with	   a	  prime	  role	  for	  Tfh	  IFN-­‐γ	  (111,112).	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The	  effect	  of	  PI3K	  inhibitors	  on	  lupus	  has	  been	  analyzed	  in	  different	  models.	  In	  the	  MRL-­‐lpr	  model	  of	  lupus,	  Barber	  et	  al.	  described	  a	  preventive	  and	  therapeutic	  effect	   of	   the	   p110γ	   inhibitor	   AS605240	   on	   autoantibodies,	   proteinuria,	   and	  reduced	  number	  of	  pathogenic	  CD4+	  memory	  T	  lymphocytes	  due	  to	  enhanced	  cell	  death	   (113),	   a	   finding	   that	   was	   also	   observed	   in	   the	   p65PI3K	   transgene	   mouse	  model	   of	   lupus	  when	   p110γ	  was	   deleted	   (114).	   Resistance	   to	   activation-­‐induced	  cell	  death	  in	  T	  lymphocytes	  is	  an	  important	  factor	  to	  SLE	  development,	  as	  shown	  in	  the	  enhanced	  PI3K	  activity	  in	  lymphocytes	  from	  SLE	  patients	  due	  to	  higher	  p110δ	  (115);	   this	   enhanced	   resistance	   to	   activation	   induced	   cell	   death	   was	   abolished,	  upon	  inhibition	  of	  p110δ	  with	  IC87114,	  particularly	  in	  the	  memory	  T	  cells	  that	  are	  enhanced	   in	   these	   patients	   (115).	   Yet	   another	  model	   of	   SLE	   is	   the	   Lyn	   deficient	  mice.	  Lyn-­‐/-­‐	  mice	  have	  enhanced	  PI3K	  signaling,	  and	  simple	  attenuation	  of	  p110δ	  signals	   in	   haploinsuficient	   Lyn−/−110δ+/	   D910A	   mice	   ameliorates	   the	   disease,	   with	  lower	  autoantibody	  levels	  and	  nephritis	  by	  a	  mechanism	  that	  involved	  lower	  T	  cell	  activation	  rather	  than	  attenuation	  of	  B	  lymphocyte	  responses	  (116).	  
12.c.	  Multiple	  sclerosis	  (MS)	  and	  Experimental	  Autoimmune	  Encephalomyelitis	  
(EAE).	  	  Multiple	   sclerosis	   is	   an	   inflammatory	   disease	   characterized	   by	  demyelination	   of	   the	   central	   nervous	   system	   (CNS).	   Experimental	   autoimmune	  encephalomyelitis	   is	   the	   model	   of	   choice	   for	   MS	   in	   mice,	   and	   is	   induced	   by	  immunization	  with	   proteins	   or	   protein	   fragments	   in	   susceptible	   strains	   of	  mice.	  Inflammation	   and	   axonal	   damage	   is	   si	   accompanied	   by	   infiltration	   of	   T	  lymphocytes	   and	   other	   leukocytes,	   and	   in	   certain	   cases	   by	   the	   formation	   of	  structures	   resembling	   lymphoid	   follicles;	   these	   contain	   T	   and	   B	   cells,	   plus	  professional	  antigen	  presenting	  cells.	  T	  lymphocytes	  specific	  for	  myelin	  antigens	  that	  secrete	  IFN-­‐γ,	  IL-­‐17,	  or	  IL-­‐9	  are	   able	   of	   inducing	   EAE,	   hence	   it	   is	   reasonable	   to	   assume	   that	   therapeutic	  approaches	   that	   suppress	   the	   secretion	   of	   these	   cytokines	   can	   be	   useful	   in	  controlling	   the	  evolution	  of	   the	  disease.	  Mice	  expressing	   the	  kinase-­‐dead	  mutant	  110δD910A	   had	   a	  milder	   form	   of	   EAE	   induced	   by	   the	   rat	  Myelin	   Oligodendrocyte	  Glycoprotein	   (MOG)	   peptide35-­‐55,	   and	   lower	   number	   of	   lesions	   and	   T	   cell	  inflammatory	  infiltration,	  plus	  enhanced	  apoptosis	  (86).	  As	  discussed	  in	  a	  previous	  section,	   in	   this	  study	  the	  p110δ	   inhibitor	   IC87114	   inhibited	  the	  differentiation	  of	  IFN-­‐γ	   producing	   Th1	   cells	   and	   IL-­‐17	   producing	   Th17	   cells,	   yet	   Th17	   more	  effectively	  than	  Th1,	  indicating	  a	  potential	  for	  PI3K	  as	  a	  target	  in	  MS	  therapy.	  We	  have	  recently	  used	  an	  oral	  therapeutic	  treatment	  with	  the	  dual	  p110α	  and	  DNA-­‐PK	  inhibitor	   PIK-­‐75	   to	   significantly	   inhibit	  MOG-­‐induced	  EAE	   symptoms	   (117).	   This	  was	  accompanied	  by	  in	  vitro	  observations	  showing	  that	  PIK-­‐75	  induced	  cell	  death	  in	   resting	  or	   activated	  T	  and	  B	   lymphocytes,	   or	  CD4+	  T	   lymphocyte	  proliferation	  and	   cytokine	   (IL-­‐2,	   IFN-­‐γ,	   IL-­‐17A,	   or	   IL-­‐21)	   secretion	   in	   the	   nanomolar	   range.	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Intriguingly,	  we	   have	   later	   found	   that	   other,	  more	   specific	   p110α	   inhibitors	   like	  A66	  do	  not	  have	  a	  similar	  effect	  on	  lymphocyte	  apoptosis	  (82),	  and	  it	  is	  probably	  the	  sum	  of	  p110α	  and	  DNA-­‐PK	  inhibition	  that	  produced	  the	  effect	  on	  cell	  viability	  (unpublished	  data).	  
12.d.	  Experimental	  colitis	  and	  psoriasis.	  	  Oral	   treatment	   with	   PIK-­‐75	   was	   previously	   shown	   to	   inhibit	   another	  experimental	   inflammation,	   namely	   colitis	   induced	   by	   oral	   administration	   of	  dextran-­‐sulfate,	   a	   model	   for	   human	   inflammatory	   bowel	   disease	   (118).	   In	   vitro,	  PIK-­‐75	  inhibited	  AKT	  phosphorylation,	  IKK	  activation,	  and	  NF-­‐κB	  transcription	  in	  lymphoid	  or	  monocyte	  cells	  or	  cell	   lines,	  secretion	  of	   the	   inflammatory	  cytokines	  IL-­‐6	   and	   TNF-­‐α	   by	   activated	  monocytes,	   or	   reduced	   the	   expression	   of	   adhesion	  molecules	   by	   TNF-­‐α	   in	   endothelial	   cells	   (118).	   As	   mentioned	   before,	   functional	  CD4+	  Treg	   cells	   are	  essential	   to	  prevent	   the	  development	  of	   experimental	   colitis,	  and	   mice	   expressing	   the	   kinase-­‐dead	   mutant	   110δD910A	   cannot	   prevent	   the	  development	  of	  the	  disease,	  suggesting	  the	  importance	  of	  the	  p110δ	  isoform	  to	  the	  effector	  function	  of	  Treg	  cells	  (96)	  Last,	  PI3K	  have	  a	  role	  in	  the	  psoriasis-­‐like	  dermatitis	  induced	  by	  imiquimod	  (IMQ).	   In	   this	   model,	   the	   T	   lymphocytes	   of	   the	   γδ	   TCR	   subset	   produce	   IL-­‐17	  essential	   to	   the	   clinical	   symptoms	   of	   the	   disease.	   After	   establishing	   that	   mice	  transgenic	   for	   the	   110δD910A	   inactive	   mutant	   or	   p110γ-­‐/-­‐	   knockouts	   are	   not	  susceptible	   to	  dermatitis	  and	  have	  diminished	  production	  of	   IL-­‐17A	  and	  F	  (119),	  Roller	  et	  al.	  went	  on	  to	  show	  that	  the	  p110δ	  inhibitor	  IC87114	  or	  p110γ	  inhibitors	  like	  AS605240	  inhibited	  IL-­‐17	  and	  IFN-­‐γ	  production	  by	  activated	  peripheral	  blood	  lymphocytes	   from	  psoriatic	  and	  healthy	  donors,	  or	   IFN-­‐γ	  production	  by	  activated	  blood	  TCRγδ	  T	  lymphocytes	  (119).	  
13.	   PI3K	  AND	  CANCER:	   IMPACT	  OF	  PI3K	   INHIBITORS	  ON	  CANCER	  CELLS	  AND	  
ANTI-­‐CANCER	  IMMUNITY:	  A	  DOUBLE-­‐EDGED	  SWORD?	  Tumor	   cells	   can	   express	   tumor	   antigens	   of	   various	   kinds	   that	   can	   elicit	  efficient	   immunity	   as	   an	   extrinsic	   mechanism	   to	   control	   and	   suppress	   cancer	  growth	   (immunosurveillance),	   establishing	   a	   dynamic	   equilibrium	   or	   even	  complete	   rejection	   of	   tumor	   cells.	   However,	   tumor	   specific	   responses	   can	   also	  promote	   tumor	   growth	   through	   the	   selection	   of	   rare	  mutant	   tumor	   cells	   able	   of	  oppose	  or	  evade	  the	  immune	  mechanisms	  developed	  by	  the	  host	  (immunoediting)	  (120,121).	  CD8	  T	  lymphocytes	  and	  IFN-­‐γ	  seem	  to	  be	  major	  cellular	  and	  molecular	  mediators	  of	  anti-­‐cancer	  responses.	  One	  mechanism	  used	  by	  tumor	  cells	  to	  evade	  immune-­‐mediated	   rejection	   is	   by	   expressing	   inhibitory	   B7	   family	  molecules	   like	  B7-­‐H1	  and	  B7-­‐H4	  that	  bind	  the	  inhibitory	  CD28	  family	  ligand	  programmed	  death-­‐1	  (PD-­‐1)	   expressed	   on	   the	   surface	   of	   activated	   T	   cells,	   B	   cells	   and	   macrophages	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(122).	  A	  B7	   family	  receptor	  expressed	  by	  melanoma	  and	  other	   tumor	  cells	   is	   the	  ICOS	   ligand	   that	   can	   directly	   induce	   the	   activation	   and	   expansion	   of	   ICOS-­‐expressing	   Treg	   cells	   within	   the	   tumor,	   suppressing	   anti-­‐tumor	   rejection,	   or	  alternatively	   induce	   the	   recruitment	   to	   the	   tumor	   of	   ICOS-­‐ligand-­‐expressing	  dendritic	   cells	   that	   favor	   Treg	   function	   (123-­‐127).	   Another	   inhibitory	   CD28-­‐like	  molecule	   expressed	   by	   Treg	   cells	   is	   CTLA-­‐4	   (Cytotoxic	   T-­‐Lymphocyte	   Antigen	   4,	  CD152).	  It	  is	  not	  surprising,	  then,	  that	  antibodies	  blocking	  CTLA-­‐4	  or	  the	  PD-­‐1/PD1	  ligands	   are	   currently	   used	   in	   anti-­‐cancer	   therapy,	   supposedly	   to	   unleash	  suppressed	  anti-­‐tumor	  immunity	  (128).	  Since	  p110α	   are	   frequently	  mutated	   in	   cancer,	  PI3K	   inhibitors	  directed	  at	  this	   isoform,	   alone	   or	   together	  with	   other	   kinases,	   are	   currently	   being	   tested	   in	  antitumour	  therapies	  (51).	  Although	  in	  our	  experience	  inhibition	  of	  p110α,	  alone	  or	  together	  with	  DNA-­‐PK	  can	  have	  a	  significant	   impact	   in	   immune	  responses	  and	  lymphocyte	   viability	   (82,117),	   other	   data	   suggest	   minimal	   damage	   of	   p110α	  inhibition	   to	   immune	   reactions	   and	   likely	   to	   anti-­‐tumor	   immunity	   (81).	   Thus,	   it	  might	   seem	   that	   only	   broad	   PI3K	   inhibitors,	   or	   Akt	   and	  mTOR	   inhibitors,	  might	  have	   a	   significant	   impact	   on	   anti-­‐tumor	   responses,	  whereas	   immunosuppressive	  p110δ-­‐	   or	   p110γ-­‐specific	   inhibitors	   would	   be	   of	   no	   interest	   to	   cancer	   therapy,	  except	   in	  hematologic	  malignancies	  were	   the	   levels	  of	   these	  subunits	   is	  naturally	  high.	  Interestingly,	  p110δ	  participates	  in	  antigen,	  cytokine	  and	  chemokine	  receptor	  signaling	   in	   B	   lymphocytes,	   and	   indeed	   one	   p110δ	   inhibitor	   CAL-­‐101	   has	   been	  used	  in	  the	  treatment	  of	  some	  relapsed	  or	  refractory	  B-­‐cell	  malignancies	  including	  chronic	   lymphocitic	   leukemia	   (CLL),	   non-­‐Hodgkin’s	   lymphoma	   (NHL),	   acute	  myeloid	   leukemia	   (AML),	   and	   multiple	   myeloma	   (MM),	   with	   clear	   clinical	  responses	   in	   CLL	   and	   some	   NHL	   (49,129).	   Surprisingly,	   this	   is	   due	   in	   part	   to	  inhibition	  of	  signals	  delivered	  by	  the	  tumor	  environment	  that	  sustain	  leukemia	  and	  lymphoma	  cells.	  	  It	   is	   yet	   more	   surprising	   the	   data	   showing	   that	   p110δ	   inhibitors	   can	   be	  useful	   in	   the	   treatment	   of	   solid	   tumors	   that	   do	   not	   harbor	   p110δ	   mutations.	  Tzenaki	  et	  al.	  have	  reported	  that	  breast	  and	  prostate	  cancer	  cells	  can	  possess	  high	  levels	   of	   p110δ	   that	   not	   only	   enhance	   cellular	   PI3K	   activity	   but	   also	   indirectly	  inhibit	   the	   tumor	   suppressor	   phosphatase	   PTEN	   via	   RhoA	   and	   ROCK	   activation,	  further	   enhancing	   PtdIns(3,4,5)P3	   levels	   (48,49).	   Thus,	   p110δ-­‐selective	   PI3K	  inhibitors	   might	   be	   useful	   in	   certain	   solid	   tumor	   therapy	   by	   directly	   inhibiting	  p110δ	   signaling	   as	   well	   as	   by	   indirectly	   activate	   PTEN	   to	   diminish	   general	  PtdIns(3,4,5)P3	  levels.	  At	  the	  same	  time,	  the	  use	  of	  p110δ	  inhibitors	  in	  these	  cases	  does	  have	  a	  true	  danger	  for	  suppressing	  anti-­‐tumor	  immune	  responses,	  but	  also	  to	  responses	  against	  pathogens.	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14.	  CONCLUDING	  REMARKS	  Research	   in	   recent	   years	   has	   accumulated	   evidence	   showing	   the	   essential	  role	  of	  class	   I	  PI3K	  and	  their	  molecular	   targets	   in	  cancer	  and	   immune	  responses,	  and	   the	  potential	  benefits	  of	  PI3K	   inhibitors	   to	   treat	  neoplastic	  and	  autoimmune	  diseases.	  The	  therapeutic	  potential	  of	  PI3K	  inhibitors	  in	  cancer	  has	  prompted	  the	  discovery	   of	   many	   different	   molecules	   by	   the	   pharmaceutical	   industry	   whose	  utility	  in	  immune-­‐based	  diseases	  needs	  to	  be	  tested.	  Many	  of	   the	  newly	  developed	  PI3K	   inhibitors	   also	   inhibit	  other	  molecules	  like	  mTOR	  or	  DNA-­‐PK	   fulfilling	   important	   functions	   in	  different	   types	  of	   cells,	   so	  that	  chronic	  treatment	  with	  these	  drugs	  might	  produce	  deleterious	  effects	  on	  the	  host	   in	   the	   long	   term	   (129).	   According	   to	   currently	   available	   data,	   the	   PI3K	  inhibitors	   under	   clinical	   or	   preclinical	   study	   are	   reasonably	   well	   tolerated,	   and	  these	   include	  broad	  specificity	  PI3K	  inhibitors	  or	  dual	  PI3K	  and	  mTOR	  inhibitors	  (51).	  The	  challenge	  now	  is	  to	  determine	  which	  particular	  type(s)	  of	  inhibitor(s)	  are	  of	  real	  benefit	  to	  each	  particular	  disease.	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ADDENDA:	  ABBREVIATIONS	  AND	  LIST	  OF	  PI3K	  INHIBITORS	  
Abbreviations	  ABD	   	   Adaptor	  binding	  domain	  	  AIA	   	   Adjuvant-­‐induced	  arthritis	  	  Akt	   	   Protein	  kinase	  B	  ATG13	   Autophagy-­‐related	  protein	  13	  ATM	   	   Ataxia-­‐telangiectasia	  mutated	  protein	  (ATM)	  ATR	   	   Ataxia-­‐	  and	  Rad3-­‐related	  protein	  (ATR)	  BAD	   	   Bcl-­‐2-­‐associated	  death	  promoter	  BCAP	   	   B-­‐cell	  adaptor	  for	  PI3K	  BCL6	   	   B	  cell	  lymphoma	  6	  transcription	  repressor	  BCR	  	   	   B	  cell	  receptor,	  antigen	  receptor	  of	  B	  lymphocytes	  BH	   	   BCR-­‐homology	  GTPase	  activation	  domain	  Btk	   	   Bruton’s	  tyrosine	  kinase	  BTLA	   	   B-­‐and	  T-­‐lymphocyte	  attenuator,	  CD272	  CIA	   	   Collagen-­‐induced	  arthritis	  	  CNS	   	   Central	  nervous	  system	  	  CTLA-­‐4	   Cytotoxic	  T-­‐Lymphocyte	  Antigen	  4,	  CD152	  DNA-­‐PKcs	   DNA-­‐dependent	  protein	  kinase	  catalytic	  subunit	  EAE	   	   Experimental	  Autoimmune	  Encephalomyelitis	  	  Erk	   	   Extracellular	  signal-­‐regulated	  kinase	  FLS	   	   Fibroblast-­‐like	  synoviocyte	  	  FYVE	   	  Fab	  1	  (yeast	  orthologue	  of	  PIKfyve),	  YOTB,	  Vac	  1	  (vesicle	  transport	  protein),	  and	  EEA1	  domain	  FOXO	   	   forkhead	  transcription	  factor/forkhead	  box	  O	  transcription	  factors	  GAP	   	   GTPase	  activating	  factors	  GC	   	   Germinal	  center	  	  GEF	   	   Guanine	  nucleotide	  exchange	  factors	  G	  proteins	   Heterotrimeric	  Guanine	  nucleotide-­‐binding	  proteins	  GPCR	   	   G	  protein–coupled	  receptor	  	  GSK-­‐3	   	   Glycogen	  synthase	  kinase	  3	  ICOS	   	   Inducible	  costimulator,	  CD278	  ITAM	   	   Immunoreceptor	  Tyrosine-­‐based	  activation	  motif	  Itk	   	   Interleukin-­‐2-­‐inducible	  T-­‐cell	  tyrosine	  kinase	  IKK	   	   IκB	  kinase	  HEAT	   	   Huntington,	  Elongation	  Factor	  3,	  PR65/A,	  TOR	  domains	  LAT	  	   	   Linker	  of	  activation	  of	  T	  cells	  MAPK	  	   Mitogen	  activated	  protein	  kinase	  MHC	   	   Major	  Histocompatibility	  Complex	  MOG	   	   Myelin	  Oligodendrocyte	  Glycoprotein	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MS	   	   Multiple	  sclerosis	  mTOR	  	   Mechanistic	  Target	  of	  Rapamycin	  mTORC1	   Complex	  of	  mTOR	  containing	  Raptor	  mTORC2	   Complex	  of	  mTOR	  containing	  Rictor	  NFAT	   	   Nuclear	  factor	  of	  activated	  T-­‐cells	  NF-­‐κB	  	   Nuclear	  factor	  κ-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	  NK	   	   Natural	  killer	  lymphocytes	  S6K	   	   p70	  S6	  kinase	  PD-­‐1	   	   Programmed	  death-­‐1,	  CD279	  PDGF	   	   Platelet-­‐derived	  growth	  factor	  	  PDK1	   	   Phosphoinositide-­‐dependent	  kinase	  1	  PGE2	   	   Prostaglandin	  E2	  	  PH	   	   Pleckstrin	  homology	  domain	  PIKK	   	   PI3K-­‐like	  protein	  kinases	  PI3K	   	   Phosphoinositide-­‐3	  kinases	  (PI3Ks)	  PKCθ 	   Protein	  kinase	  θ	  	  PKB	   	   Protein	  kinase	  B	  PLCγ 	   Phospholipase	  C	  γ	  	  PROPPIN	   β-­‐propeller	  that	  bind	  phosphoinositide	  species	  PTEN	   	   Phosphatase	  and	  Tensin	  Homologue	  	  PtdInsP	   Phosphorylated	  inositol	  lipids	  PX	   	   Phox	  homology	  domain	  RHEB	   	   Ras	  homologue	  enriched	  in	  brain	  	  SH2	   	   Src	  homology	  region	  2	  domain	  SH3	   	   Src	  homology	  region	  3	  domain	  SHP-­‐1	  	  	   SH2	  domain-­‐containing	  Inositol	  Phosphatase-­‐1	  SHP-­‐2	  	  	   SH2	  domain-­‐containing	  Inositol	  Phosphatase-­‐2	  SGK1	   	   Serum-­‐	  and	  glucocorticoid-­‐inducible	  kinase	  (SGK)	  1	  SLE	   	   Systemic	  Lupus	  Erythematosus	  	  TCR	  	   	   T	  cell	  receptor,	  antigen	  receptor	  of	  T	  lymphocytes	  Tfh	   	   Follicular	  helper	  T	  cells	  TNF	   	   Tumor	  necrosis	  factor	  	  TSC1,	  TSC2	   Tuberous	  sclerosis	  complex	  proteins	  1	  and	  2	  Treg	   	   CD4+	  regulatory	  T	  lymphocytes	  TRIM	   	   T	  cell	  receptor	  (TCR)-­‐interacting	  molecule	  WD	  repeat	   WD40	  repeat,	  β-­‐transducin	  repeat	  
PI3K	  inhibitors	  A66	   	   	   PI3K	  inhibitor,	  p110α	  	  AS-­‐605240	   	   PI3K	  inhibitor,	  p110γ	  	  AS-­‐604850	   	   PI3K	  inhibitor,	  p110α/γ	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CAL-­‐101	   	   PI3K	  inhibitor,	  p110δ	  ETP-­‐46321	   	   PI3K	  inhibitor,	  p110α/δ	  	  GDC-­‐0941	   	   PI3K	  inhibitor,	  pan-­‐PI3K	  	  IC87114	   	   PI3K	  inhibitor,	  p110δ	  	  INK007	   	   PI3K	  inhibitor,	  p110δ	  LY294002	   	   PI3K	  inhibitor,	  broad-­‐spectrum	  MLN1117	   	   PI3K	  inhibitor,	  p110α	  	  PI-­‐103	  	   	   PI3K	  inhibitor,	  broad-­‐spectrum	  PIK-­‐75	   	   PI3K	  inhibitor,	  p110α/DNA-­‐PK	  inhibitor	  PIK-­‐90	   	   PI3K	  inhibitor,	  broad-­‐spectrum	  TGX-­‐221	   	   PI3K	  inhibitor,	  p110β	  	  Wortmannin	  	  	   PI3K	  inhibitor,	  broad-­‐spectrum	  ZSTK474	   	   PI3K	  inhibitor,	  broad-­‐spectrum	  	  	   	  
